Statistical Methods for Treatment Effects with Treatment Switching by Chu, Fang-I
UC Santa Barbara
UC Santa Barbara Electronic Theses and Dissertations
Title
Statistical Methods for Treatment Effects with Treatment Switching
Permalink
https://escholarship.org/uc/item/4r82m5s5
Author
Chu, Fang-I
Publication Date
2015
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
UNIVERSITY OF CALIFORNIA
Santa Barbara
Statistical Methods for Treatment Effects with
Treatment Switching
A Dissertation submitted in partial satisfaction
of the requirements for the degree of
Doctor of Philosophy
in
Statistics and Applied Probability
by
Fang-I Chu
Committee in Charge:
Professor Yuedong Wang, Chair
Professor David Hinkley
Professor John Hsu
Professor Wendy Meiring
December 2015
The Dissertation of
Fang-I Chu is approved:
Professor David Hinkley
Professor John Hsu
Professor Wendy Meiring
Professor Yuedong Wang, Committee Chairperson
November 2015
Statistical Methods for Treatment Effects with Treatment Switching
Copyright c© 2015
by
Fang-I Chu
iii
Acknowledgements
First and foremost, I would like to express my deepest gratitude to my advi-
sor, Professor Yuedong Wang. His continuous guidance, support, and care make
the research presented in this dissertation possible. I am grateful that Professor
Yuedong Wang has inspired me with great ideas in my research work, giving me
career advice and great help in many other areas. I also would like to thank Pro-
fessor David Hinkley, my committee member and mentor through graduate study.
I would not be able to get through confronted struggles without his consistent
patience and caring guide. My gratitude also goes to Professor John Hsu and
Wendy Meiring, my committee members, who encouraged me greatly, and gave
precious advice about career and life.
I would never have been able to finish my dissertation without the guidance
of the faculty members, help from friends, and support from my family. My time
at UC Santa Barbara was made enjoyable in large part due to the pleasure to
study and work with many great graduate students who have become my lifetime
friends. I also want to thank them for their help and useful discussion during my
graduate study.
Finally, I would like to thank my parents, Chun-Lan Chen and Jer-Hrong Chu,
for all their unconditional love and support, allowing me to pursue my academic
career with full devotion.
iv
Curriculum Vitæ
Fang-I Chu
Education
2015 Doctor of Philosophy in Statistics and Applied Probability, De-
partment of Statistics and Applied Probability, University of Cal-
ifornia, Santa Barbara
2011 Master of Art in Applied Statistics, University of California,
Santa Barbara
2009 Master of Art in Mathematics, San Francisco State University
2006 Master of Art in Economics, San Francisco State University
2004 Bachelor of Art in International Business, I-Shou University, Tai-
wan
Experience
2015 Intern Statistician, Santa Barbara Actuaries Inc.
2011-2015 Computer Systems Assistant, Department of Statistics and Ap-
plied Probability, University of California, Santa Barbara.
2013 Intern Biostatistician, Shire plc, Wayne, PA.
2010-2015 Teaching Assistant, Department of Statistics and Applied Prob-
ability, University of California, Santa Barbara
2009-2010 Readership Assistant, Department of Statistics and Applied Prob-
ability, University of California, Santa Barbara.
2007-2009 Readership Assistant, Department of Mathematics, San Fran-
cisco State University
2007 On-line Teaching Assistant, Department of Mathematics, San
Francisco State University
v
Abstract
Statistical Methods for Treatment Effects with Treatment
Switching
Fang-I Chu
Treatment switching occurs frequently in clinical trials and other medical stud-
ies. Ignoring switching usually leads to biased and inefficient estimates of the
treatment effect. More research is necessary to account for possible correlation
between switching time and survival time. This thesis consists of two topics,
treatment switching in clinical trials in Chapters 1-4 and treatment switching in
dialysis studies in Chapters 5 and 6. Our research work addresses the treatment
switching scenario through three approaches: (1) include a frailty term to acceler-
ated failure time models, along with a logistic model to accommodate prognostic
status, (2) evaluate treatment effect based on the latent event time and (3) quan-
tify the switch effect using a varying coefficient Cox model. The proposed methods
are applied to investigate the dynamic effect of change in dialysis vascular access
in dialysis patients. The statistical analysis using above methods consistently sug-
gests that hemodialysis (HD) patients with access change from catheter (CATH)
to arteriovenous (AV) have lower mortality risk than those without access change
and early switching is more beneficial.
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Chapter 1
Treatment Switching in Clinical
Trials
1.1 Introduction
Treatment switching occurs frequently in clinical trials (Morden, Lambert, La-
timer, Abrams and Wailoo 2011). It happens when patients fail to comply with
the original assigned regime. There are two situations: drop-in and drop-out.
Drop-in occurs when disease progresses in patients of the control group such that
these patients require treatment. Drop-out, on the other hand, happens when
patients in treatment arm have difficulty to stick with the procedure, possibly
due to side effects caused by the treatment or a change of will. Fail to account
for either situation as we attempt to evaluate the treatment effect would lead to
potentially biased conclusions.
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We review some existing methods in Sections 1.2 to 1.5 and discuss limitations
of the existing methods in Section 1.6.
1.2 Intention-To-Treat and Per-Protocal
The intention-to-treat (ITT) is the traditional method to cope with the treat-
ment switching in clinical trials. It ignores the switching between treatment arms,
and draws conclusion based on treatment arms which patients were randomized
to. While the statistical analysis can be carried out easily, the ITT method may
lead to underestimation of treatment effect due to the diluted treatment effect
and consequently may lose power.
The Per-Protocol (PP) approach, on the other hand, involving analysis about
patients according to the treatment they actually received, usually is used to
supplement an ITT analysis. PP censors patients as they switch or excludes any
switching patient (Fergusson, Aaron, Guyatt and Herbert 2002). By doing so, PP
may introduce selection bias by not accounting for relation between the switching
and the prognosis of disease. Another approach is to assess the effect of treatment
actually received by a patient in the Cox proportional hazard model that includes
treatment as a time-varying covariate. The model takes the form:
λi(t) = λ0(t)exp(ψRi(t)),
2
where ψ is the treatment effect, λ0(t) is the baseline hazard function and Ri(t)
takes a value of zero while the ith patient is receiving the control and 1 while
they are receiving the experimental treatment. This approach can break the ran-
domization balance and is subject to potential selection bias as the PP method,
if switching is related to prognosis.
1.3 Adjusted Hazard Ratio Method
Law and Kaldor (1996) proposed an adjusted Cox model based on the obser-
vation that patients can be divided into four groups according to their switching
patterns. Denote control and treatment arms as C and T . The groups CC and
TT stand for the patients who complied with the schemes in control and treat-
ment arms, while groups CT and TC represent those who switched from control
to treatment and vice versa. They assumed that the hazard ratio, which stands
for the relative effectiveness of control and treatment, is the same at the time of
switching treatments as at the time of randomization. This assumption is ques-
tionable since the relative effectiveness of the control and treatment at the time of
switching could be smaller, due to the patients who switched being at an advanced
stage of disease when the treatments are less effective. Furthermore, the grouping
criterion is based on a future event; that is to say, a patient randomized to control
C will be in group CT if the patient switches to treatment regime later. The use
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of covariates depending on future event is problematic for proportional hazards
regression.
1.4 Accelerated Failure Time Model
1.4.1 Counterfactual Time
Robins and Tsiatis (1991) introduced an accelerated failure time model to
estimate the true efficacy of a treatment. Consider a randomized trial with two
arms, where Ri = 0 indicates patient i in the control arm, while Ri = 1 indicates
patient i in the treatment arm. Let Ti be the actual observed survival time of the
ith patient. A counterfactual event time Ui that would have been observed for a
patient if he/she has not been switched to treatment arm is computed based on an
acceleration factor eψ. The factor eψ stands for the magnitude of multiplicative
effect on survival time from receiving treatment. Assuming treatment is beneficial,
then ψ < 0. It is assumed that Ui is independent of Ri based on randomization.
Denote the switching time as Si and switching status as 4i, where 4i = 0 for
no switch and 1 for switch. Switching is only allowed from the control to the
treatment arm. Robins and Tsiatis (1991) and Branson and Whitehead (2002)
made the follows assumption for the counterfactual time
4
Ui =

Ti, Ri = 0 and 4i = 0,
Si + e
ψ(Ti − Si), Ri = 0 and 4i = 1,
eψTi, Ri = 1.
(1.1)
The causal AFT model relates counterfactual time Ui to observed survival
time Ti. Maximum likelihood estimation for treatment effect is obtainable if one
specifies a parametric distribution for U . However, the AFT model fails to account
for the possible correlation between Ui and Si and neglects the fact that disease
prognosis might be strongly related to the change in treatment regime.
1.4.2 Iterative Parameter Estimation
Branson and Whitehead (2002) used an iterative parameter estimation (IPE)
algorithm to compute randomization based effect estimators (RBEE) for ψ. Ti
and Si are assumed to be independent. The algorithm is motivated by the need to
adjust the treatment estimate to account for patients in the control arm switching
to the treatment arm. The method is implemented in the following steps:
Initiation Obtain an initial estimate of ψ, ψ0, by comparing the randomized
groups using a parametric AFT model.
Iteration At iteration j, transform the observed survival times for all patients
who switched treatment in control arm to create projected counterfactual
5
times using
U∗i = Si + e
ψj−1(Ti − Si),
where ψj−1 is the estimate of ψ at iteration j − 1. Fit an AFT using U∗i to
obtain an updated estimate ψj. Repeat the iteration step until |eψj−eψj−1 | <
, where  is a small positive number that controls the precision.
1.4.3 Estimation Using Joint Parametric Model
Let C1, . . . , Cn be independent non-negative censoring times which are inde-
pendent of observed survival times. Let Ti be the survival time for patient i with
associated censoring time Ci and censoring indicator δi. The observations are
Yi = min{Ti, Ci}, and δi = 1 when Ti ≤ Ci and δi = 0 otherwise. Let Si be
the switching time of patient i from the control to the treatment arm and the
treatment history can be considered as a binary process Xi(t) with 0 representing
control and 1 representing treatment. For a patient who switched to the treatment
arm, the counterfactual time Ui = Si + e
ψ(Ti − Si) can be rewritten as
Ui(ψ) =
∫ Ti
0
exp [ψXi(t)] dt.
Robins and Tsiatis (1991) assumed that Ui is identically distributed across
the randomized groups. However, if Ti is a censored survival time, then Ui(ψ) is
censored at
6
Di(ψ) =
∫ Ci
0
exp[ψXi(t)]dt,
where Xi(t) may potentially depend on factors such as underlying prognosis that
causes change in treatment regime. Therefore, even when censoring on the T -
scale is non-informative, censoring on U -scale is likely to be informative which is
illustrated as follows. Assuming the treatment is beneficial, that is ψ < 0, we
have
P (Ui > Ci|Ri = 0,4i = 0) = P (Ti > Ci),
P (Ui > Ci|Ri = 0,4i = 1) = P (Si + eψ(Ti − Si) > Ci)
< P (Si + (Ti − Si) > Ci)
= P (Ti > Ci).
That is to say, individuals in the control group who switched to treatment are
more likely to be censored than those did not switch since experimental treat-
ment increases the counterfactual time Ui.
Walker, White and Babiker (2004) assumed a parametric model for Ui and Si
with joint density f(s)f(u|s). The aim is to remove the informative censoring from
the dependence between censoring time Ci and Si. The problem of informative
censoring is resolved whenever the censoring time on the U -scale is independent
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of Ui conditional on the switching time Si. Walker et al. (2004) proposed a para-
metric model that consists of three parts:
1. Causal model: AFT model defined in (1.1) that relates Ui and Ti.
2. A bivariate frailty model for Ui and Si: this model is based on the assump-
tion that U and S are independent given a common frailty. Denote Hu(u)
and Hs(s) as the marginal cumulative hazards for U and S. Walker et al.
(2004) considered two distributions for the common frailty: positive stable
distribution and gamma distribution.
3. Models for the marginal cumulative hazards for Ui and Si: Walker et al.
(2004) assumed that marginal cumulative hazards for Ui and Si are Weibull
or Gompertz.
Walker et al. (2004)’s joint parametric model aims to remove the informa-
tive censoring problem by modeling the relation between Ui and Si. Although
the problem of informative censoring can be resolved through modeling the joint
parametric model, the independent assumption between Ui|Si and Ci is problem-
atic and difficult to check in practice since Ui is unobserved. On the other hand,
the assumption of independence between Ti and Ci is standard and intuitive.
8
1.4.4 Switching Effects
The failure to account for the relationship between switch status and prognosis
might introduce bias. Shao, Chang and Chow (2005) introduced a switching effect
ω(s) in the AFT model. The inclusion of switching status accounts for the effect
from potential factors related to switching status, such as disease prognosis, or
other factors which makes a patient more likely to switch the regime. For the
case where patients may switch from either groups, Shao et al. (2005) assumed
the following model conditional on Si,
Ui = Si + e
ψ(1−2Ri)ωRi,η(Si)(Ti − Si),
where ωRi,η(Si) models the switching effect. Shao et al. (2005) suggested that
function ω should be close to 1 when s is approaching 0, that is, switching effect
is negligible at an early stage. This may not be appropriate since patients switch
early may be sicker patients.
Assume that the survival time Ti for the control arm follows distribution Fθ(t),
where θ is an unknown parameter vector. The survival time distribution can be
written as P (Ti ≤ t) = Fθ(eψRit), t > 0.
The distributions of the survival times conditional on Si for patients who
switched treatments are
9
P (Ti ≤ t) = P (Ui ≤ Si + eψ(1−2Ri)ωRi,η(Si)(t− Si))
= Fθ(e
ψRi
[
Si + e
ψ(1−2Ri)ωRi,η(Si)(t− Si)
]
)
= Fθ(e
ψRiSi + e
ψ(1−Ri)ωRi,η(Si)(t− Si)).
Define Si = ∞ when patient i who never switches. Then the conditional
likelihood function given Si is
L(θ, ψ, η) =
∏
i:Si=∞
[
eψRifθ(e
ψRiYi)
]δi [
1− Fθ(eψRiYi)
]1−δi
×
∏
i:Si<∞
[
eψ(1−Ri)ωRi,η(Si)fθ
[
eψRiδi + e
ψ(1−Ri)ωRi,η(Si)(Yi − Si)
]]δi
× [1− Fθ [eψRiSi + eψ(1−Ri)ωRi,η(Si)(Yi − Si)]]1−δi .
The use of conditional likelihood is problematic since it may lead to biased
estimates (Zeng, Chen, Chen, Ibrahim and Amgen Research Group 2012).
1.5 Semi-Parametric Semicompeting Risks Tran-
sition Approach
Zeng et al. (2012) proposed to model the observed survival times using a
semi-parametric hazard model. They introduced a mixed semicompeting risks
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transition model to take prognosis factor into account for the disease-progression
and non-disease-progression subpopulations. Time-to-death is the only event time
of interest for non-disease-progression subpopulation, while both time to disease
progression and event of death are considered for disease-progression subpopula-
tion. This method of modeling event times can be viewed as an illness-death with
four states: alive with/without progression, and dead with/without progression.
Zeng et al. (2012) assumed Cox proportional hazard models for the time to the
intermediate event and time from the intermediate event to death. One of the
potential problems of the AFT model in Section 1.4 is the failure to account for
the relationship between switching status and disease prognosis, which also might
have impact on treatment effect. Zeng et al. (2012)’s approach not only allows the
treatment effect at switching to be completely different from the baseline treat-
ment effect, but also is able to handle both baseline covariates and prognostic
covariates at switching.
1.6 Limitations of Existing Methods and Pro-
posed Methods
Robins and Tsiatis (1991) and Branson and Whitehead (2002) proposed the
accelerated failure time model (AFT) to relate the counterfactual time Ui and
11
observed time Ti. The relationship between switching time and survival time has
not been considered. The dependence between Ti and Si needs to be considered
because a patient is more likely to switch when his/her prognosis is more severe.
The conditional likelihood approach used in Shao et al. (2005) may lead to biased
estimates.
Walker et al. (2004) assumed a joint parametric model for (Ui, Si) to account
for the dependence between Ui and Si with the aim of removing the informative
censoring in Ui. Although the problem of informative censoring can be resolved
through modeling joint parametric model, the independence assumption between
Ui|Si and Ci is problematic and difficult to check. Furthermore, the maximum
likelihood does not yield randomization-respecting estimators because the original
randomization balance has not been used in the estimation procedure. That is,
the estimated values of Ui are not guaranteed to be balanced between random-
ized groups. Walker et al. (2004) obtained a randomization-respecting estimator
through an adjustment procedure to ensure the randomization balance.
Zeng et al. (2012) described the different behaviors of the two subpopula-
tions by including prognosis factors. The assumption of the treatment effect from
progression depends only on the event of progression may be inappropraite. In
Chapter 2, we will look at Zeng et al. (2012)’s model more closely and propose a
12
semi-competing risk model with a frailty term that models the relation between
time to progression and time from progression to death. In Chapter 3, an AFT
model will be proposed as an extension of Zeng et al. (2012)’s model. In Chapter
4, we further develop the AFT model with a frailty term.
13
Chapter 2
Semi-Competing Risk Models
2.1 Introduction
Zeng et al. (2012) proposed to model the observed survival times using a semi-
parametric hazard model. They introduced a mixed semicompeting risks transi-
tion model to take prognosis factor into account for the disease-progression and
non-disease-progression subpopulations, where disease-progression population will
eventually develop disease progression before death while non-disease-progression
population will never experience disease progression. Therefore, time-to-death
is the only event time of interest for non-disease-progression subpopulation, and
both time to disease progression and time from progression to the event of death
are considered for disease-progression subpopulation.
14
2.2 The Semi-Computing Risk Model
2.2.1 Notations
In the remainder of this thesis, we will use the following notations:
• Indicator for progression status P =

0, no progression before death,
1, progression before death.
• Indicator for switching status V =

0, no switch,
1, switch.
• Indicator for randomized regime R =

0, control,
1, treatment.
• Indicator for censoring δ =

0, censored,
1, uncensored.
• TD denotes time-to-death.
• TP denotes time to disease progression.
• TV denote time to switch event.
• TG stands for time from disease progression to death.
• X represents baseline covariates.
• Z reflects covariates collected at progression, as prognostic factors for the
switching decisions.
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• Time-dependent indicator for the switch event U(t) =

1, if t ≥ TV ,
0, if t < TV .
• hD(t|R,X, P = 0), hP (t|R,X, P = 1) and hG(t|R,Z, V, P = 1, TP ) are the
conditional hazard functions of TD, TP , and TG, respectively.
• hDU (t|U(t)),X denotes the hazard function of TD given time-dependent in-
dicator for switch event U(t).
• h0(t), h1(t) and h2(t) are unknown baseline hazard functions for TD, TP and
TG.
• SD(t|R,X, P = 0), SP (t|R,X, P = 1) and SG(t|R,Z, V, P = 1, TP ) are con-
ditional survival functions of TD, TP , and TG, respectively.
• S0(t), S1(t) and S2(t) are unknown baseline survival functions.
• C denotes censoring time.
• Y denotes observed failure time.
• W denotes the observed disease progression time.
2.2.2 The Model
Zeng et al. (2012)’s model is given by the following equations:
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logit{Pr(P = 1|R,X)} = α0 + α1R + α2X, (2.1)
hD(t|R,X, P = 0) = h0(t)exp [β00R + β01X] , (2.2)
hP (t|R,X, P = 1) = h1(t)exp [β10R + β11X] , (2.3)
hG(t|R,Z, V, P = 1, TP ) = h2(t)exp
[
β20R + β21V (1−R) + βT2 (ZT , TP )T
]
, (2.4)
where h0(t), h1(t) and h2(t) are unknown baseline hazard functions, and α’s and
β’s are regression coefficients.
Equation (2.1) models the probability of progression given baseline covariates
X and randomized treatment R. Equation (2.2) models hazard function for non-
disease-progression group given X and R. For disease-progression group, equation
(2.3) models the hazard function of time to progression TP given X and R, and
equation (2.4) models the hazard function of time TG from progression to death
given V , R, Z and TP . Notice that equations (2.3) and (2.4) apply to the disease-
progression group only.
The ultimate aim of Zeng et al. (2012)’s model is to compare the survival
function of death time to the setting when no subjects have switching. Zeng
et al. (2012) adopted a counterfactual outcome framework by defining T ∗D(a) for
a = 0 as control or 1 as treatment to be a potential survival time when a sub-
ject receives treatment regime and never changes treatment status and letting
Sa(t) = P (T
∗
D(a) > t). The goal is to compare S1(t) and S0(t). As in Robins and
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Tsiatis (1991)’s causal model framework, Zeng et al. (2012) made the following
assumptions.
Assumption 1. Treatment R is completely randomized and T ∗D(a) = TD(a)
if a subject never changes treatment regime.
Assumption 2. Given (R = 0,Z, TP = s), that is, a subject in the control
arm has disease progression at time s and covariates Z, or (R = 1,Z, TP = s), V
is independent of the potential outcomes {T ∗D(0), T ∗D(1)}. Denote fX(x) and fZ(z)
as the density functions for X and Z, the potential survival function of treatment
a, P (T ∗D(a) > t), can be obtained through integrating the conditional survival
function for scenarios of P = 0 and P = 1.
In other words, Sa(t) can be expressed in terms of the parameters in model
(2.1), (2.2), (2.3), and (2.4), and the distribution of X and Z given (X, P = 1, R).
All the model parameters, including α’s, β’s and baseline hazard functions, are
estimated via nonparametric maximum likelihood. Therefore, Sa(t) is estimable
so that the casual effect of treatment can be estimated.
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Assumption 3. The censoring time is independent of TD, TP and TG given
the observed covariates.
Assumption 4. For progression subjects, TP is independent of Z given R
and X.
2.2.3 Limitations
Zeng et al. (2012) summarized the different behaviors of the two subpopula-
tions through semi-parametric hazard model by including prognosis as a binary
factor, depending on whether the disease of patient will progress before death
time or not. Zeng et al. (2012)’s model, however, is in the form of proportional
hazards with the assumption that the hazards of two individuals is related by
a proportionality constant independent of t. Such an assumption might be too
restrictive for some applications. Furthermore, in Zeng et al. (2012)’s model, time
to progression is considered as a covariate in the Cox PH model for the time
from progression event to death. An alternative approach to model the relation
between time to progression and time from progression to death is to include a
frailty term. We propose an accelerated failure time (AFT) model with a frailty
term to account for correlation between time to progress and time from progress
to death among subjects.
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Chapter 3
Accelerated Failure Time Model
3.1 The Accelerated Failure Time Model
Zeng et al. (2012)’s model is in the form of proportional hazards with the
assumption that the hazards of two individuals is related by a proportionality
constant independent of t. Such an assumption may be restrictive for some ap-
plications. Therefore, we propose the accelerated failure time (AFT) model as
alternative approach.
An accelerated failure time model assumes that the effect of given covariates,
Z, is to speed up the time by a factor exp
[
θTZ
]
, that is, the survival function
of a subject with covariates Z at time t is the same as the survival function of a
subject with a baseline survival at a time exp(θTZ)t:
S(t|Z) = S0(exp
[
θTZ
]
t)
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where S0(t) is the baseline survival function with Z = 0. In terms of the hazard
function, above survival function can also be written as
h(t|Z) = exp [θTZ]h0(exp [θTZ] t).
We will consider the following model
logit{Pr(P = 1|R,X)} = α0 + α1R + α2X, (3.1)
SD(t|R,X, P = 0) = S0(exp [β00R + β01X] t), (3.2)
SP (t|R,X, P = 1) = S1(exp [β10R + β11X] t), (3.3)
SG(t|R,Z, V, P = 1, TP ) = S2(exp[β20R + β21V (1−R)
+ βT2 (Z
T , TP )
T ]t), (3.4)
Compare to Robins and Tsiatis (1991)’s model, the switching status 4 repre-
sents progression status P , while the switching time S represents progression time
TP , while counterfactual time could be rewritten as U = TP +exp(ψ)TG, and time
from switching to death TG could be restated as TG = exp(−ψ)(U − TP ). More-
over, Robins and Tsiatis (1991)’s model assumes all progressive patients switch,
and there are patients with switch in the treatment arm. Specifically, Robins and
Tsiatis (1991) assumes that
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P (TG > t|TP = s) = P (e−ψ(U − s) > t|TP = s)
= P (U > e−ψt+ s|TP = s)
= S0(e
−ψt+ s|TP = s). (3.5)
Respectively, for the situation of no progression in treatment arm and all
progressive patients switch (R = 0, P = 1 and V = 1), the survival distribution
of time from progression to death, TG is
SG(t|R,Z, V = 1, P = 1, TP , R = 0) = S2(exp[β21 + βT2 (ZT , TP )T ]t). (3.6)
Therefore, Robins and Tsiatis (1991)’s model is a special case of our AFT
model. In other words, when two baseline survival functions is equivalent in form
of S0(e
ψt + s|TP = s) = S2(exp[β21 + βT2 (ZT , TP )]), Robins and Tsiatis (1991)’s
model stands for proposed AFT model with all progressive patients switch and
no switch occurs in treatment arm.
TD describes the survival function of time to death in equation (3.2) as progres-
sion is unobserved (P = 0). β00 stands for the accelerated factor of the treatment
for patients without progression.
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TP describes the survival function of time to progression in equation (3.3) as
progression is present, where β10 stands for the accelerated factor of the treatment
on time to progression, while TG describes the survival time from to progression
to death in equation (3.4), where β20 stands for the accelerated factor of the treat-
ment on time to progression to death.
When randomization regime is treatment and subject stays on treatment, β20
stands for the accelerated factor of the treatment, while as randomization regime
is control and subject switches to treatment arm, β21 stands for the accelerated
factor of the treatment.
In terms of the hazard function, above model can be rewritten as
hD(t|R,X, P = 0) = h0(exp [β00R + β01X] t)exp [β00R + β01X] , (3.7)
hP (t|R,X, P = 1) = h1(exp [β10R + β11X] t)exp [β10R + β11X] , (3.8)
hG(t|R,Z, V, P = 1, TP ) = h2(exp
[
β20R + β21V (1−R) + βT2 (ZT , TP )T
]
t)
× exp [β20R + β21V (1−R) + βT2 (ZT , TP )T ] . (3.9)
We shall note, the proposed AFT model summarizes the relation between
time to progression, TP , and time from progression to death, TG, through survival
function conditional on time to progression, SG(t|TP ). An alternative approach to
account for the relation between TP and TG will be introduced in the next chapter.
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3.2 Estimation
The observed data can be divided into four groups of observations:
Figure 3.1: Grouping criteria by progression and censoring status shown in
flowchart.
Group 1. Subjects are observed to fail at time Y without disease progression
event occurring. These subjects have P = 0, TD = Y and δ = 1.The contribution
to the likelihood function is
hD(Y |X, R)SD(Y |X, R)P (P = 0|R,X)fX(x|R)P (R)
= h0(exp [β00R + β01X]Y )exp [β00R + β01X]S0(exp [β00R + β01X]Y )
× P (P = 0|R,X)fX(x|R)P (R), (3.10)
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where fX(x|R = a) =
∑n
j=1 I(Xj = x,Rj = a)/
∑n
j=1 I(Rj = a). Because of the
randomization, fX(x|R = a) = fX(x), and therefore, we can replace fˆX(x|R = a)
with the empirical distribution of X.
Group 2. Subjects are observed with disease progression at time W and fail
at time Y . These subjects have P = 1, TP = W , TG = Y −W , and δ = 1. The
contribution to the likelihood function is
hP (W |R,X, P = 1)hG(Y −W |R, V, P = 1)SP (W |R,X, P = 1)
× SG(Y −W |R, V, P = 1)P (P = 1|R,X)fX(x|R)P (R)
= hP (W |R,X, P = 1)hG(Y −W |R, V, P = 1)S1(exp [β10R + β11X]Y )
× S2(exp[β20R + β21V (1−R) + βT2 (ZT , TP )T ]P (P = 1|R,X)fX(x|R)P (R).
(3.11)
Group 3. Subjects are observed with disease progression at time W and
censored at time C. These subjects have P = 1, TP = W , TG > Y − W and
δ = 0. The contribution to the likelihood function is
hP (W |R,X, P = 1)SP (W |R,X, P = 1)
× SG(Y −W |R, V, P = 1)× P (P = 1|R,X)fX(x|R)P (R).
(3.12)
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Group 4. Subjects are only observed to be censored at time Y without disease
progression event occurring. These subjects have P = 0, with TD > Y ; or, they
may have P = 1, with TP > Y . The contribution to the likelihood function is
[SD(Y |X, R)P (P = 0|R,X) + SP (W |R,X, P = 1)P (P = 1|R,X)]fX(x|R)P (R)
= [S0(exp [β00R + β01X]Y )P (P = 0|R,X)
+S1(exp [β10R + β11X]Y )P (P = 1|R,X)]× fX(x|R)P (R) (3.13)
Let CD and CG denote the censoring time for TD and TG, respectively. We
could write observed failure time Y and observed progression time W as
Y = {TD(1− P ) + (TP + TG)P}δ + {(CD(1− P ) + (TP + CG)P}(1− δ),
W = {TD(1− P ) + TPP}δ + {CD(1− P ) + TPP}(1− δ).
The AFT model, with and without random effects, can be fitted using the
SAS procedure PROC NLMIXED. For constructed likelihood function, the
NLMIXED procedure finds MLEs for a range of non-linear, mixed effects mod-
els by maximizing an approximation to the full data likelihood function, integrated
over the random effects. The specific distribution of random effect is defined by
RANDOM statement in NLMIXED. Currently, the only distribution available
for the random effects is normal with specified mean and variance. Since the
proposed AFT model in this chapter does not contain random effect, the integra-
tion step is skipped here. The AFT model with random effect, or frailty, will be
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introduced in Chapter 4. For detailed information about PROC NLMIXED
procedure, please refer to Appendix A.1.
3.3 Simulation Study
With the aim to examine the performance of the proposed estimation proce-
dure, we conducted a simulation study by generating data from (3.1), (3.2), (3.3)
and (3.4). Specifically, for the first half of subjects are assigned to treatment
(R = 1), while the rest are assigned to control (R = 0). We assume two baseline
covariates X1
i.i.d.∼ uniform[−1, 1] and X2 i.i.d.∼ Ber(0.6). We consider two sample
sizes: n = 400 and n = 1000.
Setting α0 = 1.6, α1 = −1.8, α2 = 1 and α3 = 0.1, the progressive sta-
tus, P , is determined by (3.4). That is, P follows Bernoulli with success rate
1
{1+exp[−(1.6−1.8R+X1+0.1X2)]} . Assume that all survival times follow exponential dis-
tribution. For subjects in non-progression group with P = 0, the death time TD
is generated using (3.2) with S0(t) = exp(−t), β00 = −1, β01 = 1 and β02 = 0.2.
For subjects in progression group with P = 1, the time to disease progression TP
is generated using (3.3) with S1(t) = exp(−t), β10 = −0.5, β11 = 1 and β12 = 0.
Lastly, in order to generate the time from disease progression to death for subjects
with P = 1, the assignment of switching indicator, V , in the untreated subjects
is assumed to follow Bernoulli with success rate 1{1+exp[−(−0.1+0.3TP+0.2X1+0.5Z)]} ,
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yielding a switching rate of 43.37% and 43.295% for sample size 400 and 1000 in
the control arm. The time from disease progression to death, TG, is generated
using (3.4) with S2(t) = exp [−t], β20 = −0.3, β21 = −0.5, β22 = 0.6, β23 = −0.5,
β24 = 0.5 and β25 = −0.4. We set the study duration to be τ = 3, and the
censoring scheme is generated from a uniform distribution on (1, 7); the censoring
scheme is assumed to take the minimum of two.
The summary of the simulation study for 100 datasets is presented in Table
3.1, 3.2, 3.3, and 3.4. For n = 400, the average proportions for groups 1 to 4 are
23.92%, 45.60%, 9.58% and 20.91%, while for n = 1000, the average proportions
for groups 1 to 4 are 23.39%, 45.80%, 9.66% and 21.16%.
The following abbreviation are used in all tables: APE represents average of the
parameter estimates, SD represents sample standard deviation of the estimates,
ASD represents average of the standard deviation estimates, MSE represents mean
squared error, and CP represents coverage percentage of the 95% confidence in-
terval.
From 100 simulated dataset, the obtained MSE for average of estimates are all
below 0.1 and CP are close to 95% for both sample size 400 and 1000. We conclude
that the proposed method performed well in estimating the true parameters.
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Table 3.1: Simulation results when n = 400
Susceptibility Model
True APE Bias SD ASD MSE CP
α0 1.6 1.66 0.06 0.30 0.27 0.09 94.00
α1 −1.8 −1.88 0.08 0.31 0.33 0.10 95.00
α2 1.0 1.05 0.05 0.28 0.31 0.08 91.00
α3 0.1 0.06 0.04 0.29 0.29 0.09 96.00
Survival model of no-progression population
β00 −1.0 −0.97 0.03 0.21 0.24 0.09 92.00
β01 1.0 0.99 0.01 0.23 0.24 0.05 95.00
β02 0.2 0.23 0.03 0.23 0.26 0.05 91.00
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Table 3.2: Simulation results when n = 400
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.49 0.01 0.19 0.19 0.04 94.00
β11 1.0 1.00 0.00 0.15 0.16 0.02 96.00
β12 0.0 0.01 0.01 0.11 0.11 0.01 91.00
Gap time model of progression population
β20 −0.3 −0.27 0.03 0.18 0.19 0.03 94.00
β21 −0.5 −0.50 0.00 0.17 0.20 0.03 92.00
β22 0.6 0.61 0.01 0.12 0.11 0.01 95.00
β23 −0.5 −0.50 0.00 0.16 0.16 0.03 91.00
β24 0.5 0.51 0.01 0.16 0.15 0.03 95.00
β25 −0.4 −0.43 0.03 0.22 0.24 0.05 94.00
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Table 3.3: Simulation results when n = 1000
Susceptibility Model
True APE Bias SD ASD MSE CP
α0 1.6 1.64 0.04 0.30 0.27 0.09 94.00
α1 −1.8 −1.81 0.01 0.31 0.31 0.10 95.00
α2 1.0 1.06 0.06 0.30 0.28 0.09 91.00
α3 0.1 0.06 0.04 0.34 0.29 0.12 96.00
Survival model of non-progression population
β00 −1.0 −0.98 0.02 0.22 0.21 0.05 92.00
β01 1.0 1.06 0.06 0.25 0.25 0.07 95.00
β02 0.2 0.21 0.01 0.26 0.23 0.07 91.00
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Table 3.4: Simulation results when n = 1000
Disease progression model of progression population
True APE Bias SD ASD MSE CP%
β10 −0.5 −0.52 0.02 0.18 0.19 0.03 94.00
β11 1.0 1.00 0.00 0.15 0.15 0.01 96.00
β12 0.0 0.04 0.04 0.13 0.11 0.02 91.00
Gap time model of progression population
β20 −0.3 −0.30 0.00 0.15 0.19 0.02 94.00
β21 −0.5 −0.51 0.01 0.18 0.17 0.01 92.00
β22 0.6 0.57 0.03 0.10 0.09 0.01 95.00
β23 −0.5 −0.52 0.02 0.13 0.14 0.02 91.00
β24 0.5 0.52 0.02 0.14 0.14 0.02 95.00
β25 −0.4 −0.37 0.03 0.23 0.22 0.05 94.00
32
Chapter 4
Accelerated Failure Time Model
with Frailty
4.1 The Accelerated Failure Time Model with
Frailty
In Chapter 3, we proposed AFT model as an extension of Zeng et al. (2012)’s
model. Time to progression is considered as a covariate. An alternative approach
to account for relation between time to progression and time from progression to
death is to introduce a frailty.
4.2 Bivariate Frailty Model
Shared frailty is often used to model association between event times. When
two observed survival times depend on the same unobserved variable, called a
frailty, this common dependence induces an association between the observed
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times.
In (3.4), the relation between time to progression, TP , and time from progres-
sion to death, TG is modeled through survival function of TG condition on TP .
Frailty model, as an alternative approach to address this relation is considered
here. We propose a frailty model to account for the relation between time to pro-
gression, TP , and time from progression to death, TG. Given the common frailty
ω, we assume that TP and TG are independent. Consider a general survival time
variable T in log-linear form with a frailty term, −ω, as additive random factor,
is expressed as
log T = µ+ θTX + (−ω) + σ, (4.1)
where µ and σ are unknown location and scale parameters, while  has some spe-
cific probability distribution.
Let ψ(X, ω|θ) = exp [θTX + (−ω)]. The survival function of T ,
S(t|X, ω) = P (T ≥ t|X, ω)
= P (log T ≥ log t|X, ω)
= P (µ+ σ ≥ ln t− θTX + ω)
= P (exp [µ+ σ] ≥ t/ψ(X, ω)). (4.2)
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The baseline survival function, S0(t), the survival function of X = 0, is
S0(t) = P (exp [µ+ σ] ≥ t). (4.3)
Conditional on ω, the AFT model is assumed to hold,
S(t) = S0(exp
[
βTX + ω
]
t). (4.4)
where θ = −β. The corresponding hazard function is (Collett 2003)
h(t) = exp
[
βTX + ω
] · h0(exp [βTX + ω] t). (4.5)
Now, considering TP and TG in log-linear form with a frailty term ω, and TD
in the same form without a frailty term as
log TD = µD + θ00R + θ01X + σDD, (4.6)
log TP = µP + θ10R + θ11X + (−ω) + σP P , (4.7)
log TG = µG + θ20R + θ21V (1−R) + θT2 (ZT , TP )T + θ3(−ω) + σGG, (4.8)
where µD, µP , µG, σD, σU and σG are unknown location and scale parameters, while
D, P and G have some specific probability distributions. Given frailty ω, AFT
model of TD, TP and TG are assumed to be
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SD(t|R,X, P = 0) = S0(exp [β00R + β01X] t), (4.9)
SP,G(tp, tg|R,X,Z, P = 1, ω) = SP (tp|R,X, U = 1, ω)
× SG(tg|R,Z, V, P = 1, ω), (4.10)
= S1(exp [β10R + β11X + ω] tp)
× S2(exp[β20R + β21V (1−R)
+ βT2 (Z
T , TP )
T + β3ω]tg), (4.11)
hD(t|R,X, P = 0) = exp [β00R + β01X]h0(exp. [β00R + β01X] t),(4.12)
hP (tp|R,X, P = 1, ω) = exp [β10R + β11X + ω]
× h1(exp [β10R + β11X + ω] tp), (4.13)
hG(tg|R,Z, P = 1, ω) = exp
[
β20R + β21V (1−R) + βT2 (ZT , TP )T + ω
]
× h2(exp[β20R + β21V (1−R)
+ βT2 (Z
T , TP )
T + β3ω]]tg). (4.14)
where SP,G(tp, tg|R,X,Z, P = 1, ω) denotes joint survival function of time to
progression and time to progression to death given a frailty term and relevant
covariates when progression is present. Note θ00 = −β00, θ01 = −β01, θ10 = −β10,
θ20 = −β21, and θ3 = −β3. Note TP and TG are assumed to be independent given
ω. Also, TP in (4.11) are considered to be prognosis factor.
A logit model is used to determine the progression status,
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logit{Pr(P = 1|R,X)} = α0 + α1R + α2X, (4.15)
We assume that ω are i.i.d. N (0, σ2).
When there is no progression (P = 0), equation (4.9) describes the survival
function of time to death, TD, where β00 stands for the accelerated factor of the
treatment.
When there is a progression (P = 1), the left hand side of equation (4.10)
describes the joint survival function of time to progression, TP , and time from
progression to death, TG, given frailty term, ω, the right hand side of equation
describe the product of survival function of TU and TG. The frailty ω is a latent
variable reflecting health condition for each subject.
Furthermore, the first part and second part of equation (4.11) describes the
survival function of time to progression, TP , and the survival function of time
from progression to death, TG. In the first part, β10 stands for the accelerated
factor of the treatment before progression. The second part addresses the time af-
ter progression event: when randomized regime is treatment and subject stays on
treatment, β20 stands for the accelerated factor of the treatment after progression.
β21 stands for the accelerated factor of the treatment when patients switch from
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control to treatment. β3 models the different post-progression impact on survival
time among subjects, as the scaling parameter for frailty term in function for TG.
4.3 Estimation
The observed data can be divided into four groups of observations:
Group 1. Subjects are observed to fail at time Y without disease progression
event occurring. These subjects have U = 0, TD = Y and δ = 1.The contribution
to the likelihood function is
hD(Y |X, R)SD(Y |X, R)P (P = 0|R,X)fX(x|R)P (R)
= h0(exp [β00R + β01X]Y )exp [β00R + β01X]
× S0(exp [β00R + β01X]Y )P (P = 0|R,X)fX(x|R)P (R). (4.16)
Group 2. Subjects are observed with disease progression at time W and fail
at time Y . These subjects have P = 1, TP = W , TG = Y −W and δ = 1. The
contribution to the likelihood function is
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hP (W |R,X, P = 1, ω)hG(Y −W |R, V, P = 1, ω)
× SP,G(W,Y −W |R,X, ω)P (P = 1|R,X)fX(x|R)P (R)
= hP (W |R,X, PU = 1, ω)hG(Y −W |R, V, P = 1, ω)
× SP (W |R,X, P = 1, ω)SG(Y −W |R, V, P = 1, ω)
× P (P = 1|R,X)fX(x|R)P (R). (4.17)
Group 3. Subjects are observed with disease progression at time W and
censored at time C. These subjects have P = 1, TP = W , TG > Y − W and
δ = 0. The contribution to the likelihood function is
hP (W |R,X, P = 1, ω)SP (W |R,X, P = 1, ω)
× SG(Y −W |R, V, P = 1, ω)× P (P = 1|R,X)fX(x|R)P (R). (4.18)
Group 4. Subjects are only observed to be censored at time Y without disease
progression and without death. These subjects have P = 0, TD > Y ; or, they
may have P = 1, TP > Y . The contribution to the likelihood function is
{SD(Y |X, R)P (P = 0|R,X) + SP (W |R,X, P = 1, ω)P (P = 1|R,X)}
fX(x|R)P (R)
= [S0(exp [β00R + β01X]Y )P (P = 0|R,X)
+ S1(exp [β10R + β11X + ω]Y |ω)P (P = 1|R,X)]fX(x|R)P (R). (4.19)
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Let CD and CG denote the censoring death time for TD and TG, respectively.
We could write observed failure time Y and observed progression time W as
Y = {TD(1− P ) + (TP + TG)U}δ + {(CD(1− P ) + (TP + CG)P}(1− δ)
W = {TD(1− P ) + TPP}δ + {CD(1− P ) + TPP}(1− δ)
As in Chapter 3, the AFT model with frailty term (random effects) can
be fitted using the SAS procedure PROC NLMIXED. For constructed like-
lihood function, the NLMIXED procedure finds MLEs for a range of non-linear,
mixed effects models by maximizing an approximation to the full data likeli-
hood function, integrated over the random effects. The integration method is
specified to take default method, adaptive Gauss-Hermite quadrature (GAUSS).
The specific distribution of random effect is defined by RANDOM statement
in NLMIXED. Currently, the only distribution available for the random effects
is normal with specified mean and variance. Appendix A.2 gives an example of
PROC NLMIXED procedure.
4.4 Simulation Study
With the aim to examine the performance of the proposed estimation pro-
cedure, we conducted a simulation study by generating data from (4.9), (4.10),
(4.11) and (4.15). Specifically, the first half of subjects are assigned to treatment
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(R = 1), while the rest are assigned to control (R = 0). We assume two baseline
covariates X1
i.i.d.∼ uniform[−1, 1] and X2 i.i.d.∼ Ber(0.6).
Setting α0 = 1.6, α1 = −1.8, α2 = 1 and α3 = 0.1, the progressive sta-
tus, U , is determined by (4.15). That is, P follows Bernoulli with success rate
1
{1+exp[−(1.6−1.8R+X1+0.1X2)]} . Assume all survival times follow exponential distribu-
tion. For subjects in non-progression group with P = 0, the death time TD is
generated using (4.9) with S0(t) = exp(−t), β00 = −1, β01 = 1 and β02 = 0.2. For
subjects in progression group with P = 1, the time to disease progression TP is
generated using (4.11) with S1(t) = exp(−t), β10 = −0.5, β11 = 1 and β12 = 0.
Lastly, in order to generate the time from disease progression to death for subjects
with U = 1, the assignment of switching indicator, V , in the untreated subjects
is assumed to follow Bernoulli with success rate 1{1+exp[−(−0.1+0.3TP+0.2X1+0.5Z)]} .
The time from disease progression to death, TG, is generated using (4.11) with
S2(t) = exp [−t], β20 = −0.3, β21 = −0.5, β22 = 0.6, β23 = −0.5, β24 = 0.5,
β25 = −0.4 and β3 = 0.2. We set the study duration to be τ = 3, and the cen-
soring scheme is generated from a uniform distribution on (1, 7); the censoring
scheme is assumed to take the minimum of two.
The frailty term, ω, are i.i.d N (0, σ2). We consider three scenarios of vari-
ances, as σ2 = 0.25, 1, 2.25; for each scenario, sample sizes n = 400 and n = 1000
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are assumed. The switching rate in the control arm for each scenarios of variances
are (42.78%, 47.688%), (40.205%,40.218%), (37.88%, 37.542%). The results from
100 replicates are given in Tables 4.1 - 4.12. For n = 400, the average proportions
for group 1 to 4 are (23.41%, 44.70%, 9.52%, 22.38%), (23.51%, 42.86%, 8.64%,
25.00%), (23.41%, 40.96%, 7.75%, 27.89%), while for n = 1000, the average pro-
portions for group 1 to 4 are (23.52%, 44.95%, 9.28%, 22.26%), (23.46%,42.99%,
8.48%, 25.08%), (23.48%, 41.18%, 7.71%, 27.74%).
Similarly, as a special case that impact from subject’s health condition on time
of pre-progression and post-progression is the same, β3 is assumed to be 1 and
we do not estimate β3. The switching rate in the control arm for each scenarios
of variances are (41.34%,41.02%), (39.7%, 40.682%), (37.79%, 37.976%). The re-
sults from 100 replicates are given in Tables 4.13 - 4.24. For n = 400, the average
proportions for group 1 to 4 of each case are (23.22%, 44.25%,10.05%, 22.40%),
(23.27%,41.93%,9.7%, 25.10%), and (23.52%, 40.19%, 8.69%, 27.61%), while for
n = 1000, the average proportions for group 1 to 4 of each case are (23.33%,
44.41%, 9.71%, 22.54%), (23.63%,41.78%,9.6%, 24.96%) and (23.25%,40.00%, 8.98%,
27.70%). Overall our estimation procedure performed very well.
From 100 simulated datasets, the obtained MSE for average of estimates are
all below 0.5 and CP are close to 95% for both sample size 400 and 1000 when
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Table 4.1: Simulation results when σ2 = 0.25 and n = 400.
True APE Bias SD ASD MSE CP
σ2 0.25 0.21 0.04 0.12 0.15 0.02 93.26
Susceptibility Model
α0 1.6 1.62 0.02 0.24 0.27 0.06 98.96
α1 −1.8 −1.83 0.03 0.29 0.32 0.09 97.92
α2 1.0 1.01 0.01 0.28 0.28 0.08 94.79
α3 0.1 0.08 0.02 0.27 0.29 0.07 94.79
Survival model of no-progression population
β00 −1.0 −0.99 0.01 0.21 0.22 0.04 94.79
β01 1.0 1.05 0.05 0.24 0.24 0.06 90.63
β02 0.2 0.19 0.01 0.20 0.24 0.04 98.96
σ2 = 0.25, 1, 2.25. We conclude that the proposed estimation method performed
well.
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Table 4.2: Simulation results when σ2 = 0.25 and n = 400.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.47 0.03 0.22 0.22 0.05 91.67
β11 1.0 0.99 0.01 0.28 0.18 0.08 95.83
β12 0.0 −0.01 0.01 0.13 0.13 0.02 94.79
Gap time model of progression population
β20 −0.3 −0.31 0.01 0.20 0.20 0.04 93.75
β21 −0.5 −0.51 0.01 0.17 0.18 0.03 97.92
β22 0.6 0.60 0.00 0.14 0.14 0.02 93.75
β23 −0.5 −0.51 0.01 0.15 0.16 0.02 96.86
β24 0.5 0.52 0.02 0.14 0.15 0.02 97.92
β25 −0.4 −0.40 0.00 0.23 0.24 0.05 95.83
β3 0.2 0.27 0.07 0.68 0.71 0.47 94.00
44
Table 4.3: Simulation results when σ2 = 0.25 and n = 1000.
True APE Bias SD ASD MSE CP
σ2 0.25 0.23 0.02 0.11 0.1 0.01 92.71
Susceptibility Model
α0 1.6 1.60 0.00 0.16 0.17 0.03 95.83
α1 −1.8 −1.86 0.06 0.20 0.20 0.04 94.79
α2 1.0 1.02 0.02 0.18 0.18 0.03 96.88
α3 0.1 0.11 0.01 0.18 0.18 0.03 95.83
Survival model of no-progression population
β00 −1.0 −1.01 0.01 0.15 0.13 0.02 93.75
β01 1.0 1.03 0.03 0.13 0.15 0.02 98.96
β02 0.2 0.20 0.00 0.16 0.14 0.03 91.67
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Table 4.4: Simulation results when σ2 = 0.25 and n = 1000.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.44 0.06 0.15 0.15 0.03 92.71
β11 1.0 0.98 0.02 0.12 0.11 0.01 93.75
β12 0.0 0.00 0.00 0.09 0.08 0.01 93.75
Gap time model of progression population
β20 −0.3 −0.28 0.02 0.12 0.13 0.01 94.79
β21 −0.5 −0.49 0.01 0.12 0.11 0.01 92.71
β22 0.6 0.59 0.01 0.01 0.01 0.00 93.75
β23 −0.5 −0.53 0.03 0.11 0.10 0.01 93.75
β24 0.5 0.51 0.01 0.01 0.01 0.00 94.79
β25 −0.4 −0.39 0.01 0.15 0.15 0.02 96.88
β3 0.2 0.20 0.00 0.50 0.43 0.25 89.58
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Table 4.5: Simulation results when σ2 = 1 and n = 400.
True APE Bias SD ASD MSE CP
σ2 1.0 0.92 0.08 0.27 0.28 0.08 97.67
Susceptibility Model
α0 1.6 1.65 0.05 0.31 0.27 0.10 96.51
α1 −1.8 −1.93 0.13 0.34 0.32 0.13 95.35
α2 1.0 1.04 0.04 0.30 0.29 0.09 94.19
α3 0.1 0.11 0.01 0.29 0.29 0.08 95.35
Survival model of no-progression population
β00 −1.0 −1.01 0.01 0.25 0.22 0.06 91.86
β01 1.0 0.99 0.01 0.27 0.25 0.07 94.19
β02 0.2 0.18 0.02 0.30 0.24 0.09 86.05
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Table 4.6: Simulation results when σ2 = 1 and n = 400.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.47 0.03 0.29 0.27 0.09 89.53
β11 1.0 0.97 0.03 0.23 0.22 0.05 94.19
β12 0.0 0.01 0.01 0.17 0.16 0.03 86.05
Gap time model of progression population
β20 −0.3 −0.29 0.01 0.19 0.21 0.04 95.35
β21 −0.5 −0.51 0.01 0.16 0.19 0.03 98.84
β22 0.6 0.58 0.02 0.14 0.16 0.02 96.67
β23 −0.5 −0.54 0.04 0.15 0.16 0.03 95.35
β24 0.5 0.51 0.01 0.16 0.16 0.03 97.67
β25 −0.4 −0.34 0.06 0.23 0.25 0.06 97.67
β3 0.2 0.18 0.02 0.27 0.24 0.07 90.70
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Table 4.7: Simulation results when σ2 = 1 and n = 1000.
True APE Bias SD ASD MSE CP
σ2 1.0 0.99 0.01 0.16 0.18 0.03 97.37
Susceptibility Model
α0 1.6 1.60 0.00 0.18 0.17 0.03 94.74
α1 −1.8 −1.84 0.04 0.19 0.20 0.04 96.05
α2 1.0 1.01 0.01 0.17 0.18 0.03 100.00
α3 0.1 0.11 0.01 0.18 0.18 0.03 94.74
Survival model of no-progression population
β00 −1.0 −1.02 0.02 0.15 0.14 0.02 94.74
β01 1.0 1.03 0.03 0.16 0.15 0.03 94.74
β02 0.2 0.21 0.01 0.14 0.15 0.02 94.74
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Table 4.8: Simulation results when σ2 = 1 and n = 1000.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.47 0.03 0.17 0.18 0.03 93.42
β11 1.0 0.99 0.01 0.13 0.14 0.02 93.42
β12 0.0 0.00 0.00 0.09 0.10 0.01 94.74
Gap time model of progression population
β20 −0.3 −0.28 0.02 0.13 0.13 0.02 93.42
β21 −0.5 −0.50 0.00 0.13 0.18 0.02 93.42
β22 0.6 0.57 0.03 0.10 0.11 0.01 94.74
β23 −0.5 −0.50 0.00 0.09 0.10 0.03 96.05
β24 0.5 0.51 0.01 0.1 0.1 0.03 93.42
β25 −0.4 −0.37 0.03 0.15 0.16 0.03 94.74
β3 0.2 0.19 0.01 0.16 0.15 0.03 90.70
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Table 4.9: Simulation results when σ2 = 2.25 and n = 400.
True APE Bias SD ASD MSE CP
σ2 2.25 2.15 0.10 0.48 0.46 0.24 89.41
Susceptibility Model
α0 1.6 1.62 0.02 0.25 0.27 0.06 98.82
α1 −1.8 −1.85 0.05 0.35 0.33 0.13 95.30
α2 1.0 1.07 0.07 0.28 0.29 0.08 96.47
α3 0.1 0.09 0.01 0.27 0.30 0.07 97.65
Survival model of no-progression population
β00 −1.0 −1.00 0.00 0.27 0.23 0.07 92.94
β01 1.0 1.05 0.05 0.25 0.25 0.07 98.82
β02 0.2 0.15 0.05 0.27 0.24 0.08 95.30
51
Table 4.10: Simulation results when σ2 = 2.25 and n = 400.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.49 0.01 0.33 0.34 0.11 91.76
β11 1.0 0.99 0.01 0.27 0.27 0.07 94.12
β12 0.0 0.03 0.03 0.22 0.20 0.05 91.77
Gap time model of progression population
β20 −0.3 −0.29 0.01 0.21 0.21 0.04 94.12
β21 −0.5 −0.51 0.01 0.17 0.20 0.03 98.82
β22 0.6 0.61 0.01 0.17 0.17 0.03 92.94
β23 −0.5 −0.51 0.01 0.16 0.16 0.03 94.12
β24 0.5 0.51 0.01 0.16 0.16 0.03 98.82
β25 −0.4 −0.36 0.04 0.26 0.26 0.07 94.12
β3 0.2 0.19 0.01 0.13 0.14 0.02 95.29
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Table 4.11: Simulation results when σ2 = 2.25 and n = 1000.
True APE Bias SD ASD MSE CP
σ2 2.25 2.26 0.01 0.25 0.29 0.06 98.63
Susceptibility Model
α0 1.6 1.59 0.01 0.18 0.17 0.03 93.15
α1 −1.8 −1.79 0.01 0.21 0.20 0.04 93.15
α2 1.0 1.00 0.00 0.18 0.18 0.03 91.78
α3 0.1 0.12 0.02 0.21 0.19 0.04 90.41
Survival model of no-progression population
β00 −1.0 −1.00 0.00 0.18 0.15 0.03 84.93
β01 1.0 1.00 0.00 0.17 0.17 0.03 94.52
β02 0.2 0.24 0.04 0.18 0.15 0.03 86.30
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Table 4.12: Simulation results when σ2 = 2.25 and n = 1000.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.52 0.02 0.24 0.22 0.06 91.78
β11 1.0 1.01 0.01 0.17 0.17 0.03 91.78
β12 0.0 0.02 0.02 0.10 0.13 0.01 97.26
Gap time model of progression population
β20 −0.3 −0.30 0.00 0.14 0.13 0.02 94.52
β21 −0.5 −0.49 0.01 0.13 0.18 0.02 93.15
β22 0.6 0.59 0.01 0.11 0.10 0.01 91.78
β23 −0.5 −0.51 0.01 0.11 0.10 0.01 90.41
β24 0.5 0.50 0.00 0.09 0.10 0.01 98.63
β25 −0.4 −0.35 0.05 0.14 0.16 0.02 98.63
β3 0.2 0.18 0.02 0.08 0.09 0.01 95.89
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Table 4.13: Simulation results when σ2 = 0.25 and n = 400 with β3 = 1.
true APE bias SD ASD MSE CP
σ2 0.25 0.24 0.01 0.11 0.12 0.01 94.00
Susceptibility Model
α0 1.6 1.64 0.04 0.30 0.27 0.09 93.00
α1 −1.8 −1.85 0.05 0.37 0.32 0.14 91.00
α2 1 0.98 0.02 0.28 0.29 0.08 97.00
α3 0.1 0.11 0.01 0.27 0.29 0.07 99.00
Survival model of no-progression population
β00 −1 −0.95 0.05 0.25 0.22 0.07 95.00
β01 1 1.01 0.01 0.27 0.24 0.07 93.00
β02 0.2 0.15 0.05 0.26 0.24 0.06 95.00
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Table 4.14: Simulation results when σ2 = 0.25 and n = 400 with β3 = 1.
Disease progression model of progression population
true APE bias SD ASD MSE CP
β10 −0.5 −0.49 0.01 0.22 0.22 0.05 91.00
β11 1 1.02 0.02 0.15 0.18 0.02 99.00
β12 0 0.01 0.01 0.12 0.13 0.01 95.00
Gap time model of progression population
β20 −0.3 −0.28 0.02 0.24 0.22 0.06 95.00
β21 −0.5 −0.49 0.01 0.18 0.20 0.03 97.00
β22 0.6 0.58 0.02 0.14 0.14 0.02 97.00
β23 −0.5 −0.49 0.01 0.16 0.17 0.03 97.00
β24 0.5 0.50 0.00 0.16 0.16 0.03 95.00
β25 −0.4 −0.41 0.01 0.27 0.25 0.07 92.00
56
Table 4.15: Simulation results whenσ2 = 0.25 and n = 1000 with β3 = 1.
true APE bias SD ASD MSE CP
σ2 0.25 0.22 0.03 0.07 0.07 0.01 95.50
Susceptibility Model
α0 1.6 1.64 0.04 0.18 0.17 0.03 95.51
α1 −1.8 −1.86 0.06 0.22 0.20 0.05 94.38
α2 1 1.00 0.00 0.21 0.18 0.04 92.13
α3 0.1 0.08 0.02 0.21 0.18 0.04 89.89
Survival model of no-progression population
β00 −1 −1.02 0.02 0.14 0.14 0.02 94.38
β01 1 0.99 0.01 0.17 0.15 0.03 95.51
β02 0.2 0.20 0.00 0.14 0.14 0.02 96.63
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Table 4.16: Simulation results when σ2 = 0.25 and n = 1000 with β3 = 1.
Disease progression model of progression population
true APE bias SD ASD MSE CP
β10 −0.5 −0.47 0.03 0.16 0.14 0.03 94.38
β11 1 0.98 0.02 0.12 0.11 0.01 95.51
β12 0 0.00 0.00 0.08 0.08 0.06 96.63
Gap time model of progression population
β20 −0.3 −0.26 0.04 0.15 0.13 0.02 91.01
β21 −0.5 −0.50 0.00 0.12 0.12 0.01 98.88
β22 0.6 0.57 0.03 0.08 0.09 0.01 95.51
β23 −0.5 −0.50 0.00 0.11 0.10 0.01 93.26
β24 0.5 0.50 0.00 0.10 0.10 0.01 97.75
β25 −0.4 −0.36 0.04 0.17 0.16 0.03 91.01
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Table 4.17: Simulation Results when σ2 = 1 and n = 400 with β3 = 1.
True APE Bias SD ASD MSE CP
σ2 1.0 0.99 0.01 0.22 0.23 0.05 97.87
Susceptibility Model
α0 1.6 1.64 0.04 0.25 0.27 0.06 97.87
α1 −1.8 −1.81 0.01 0.34 0.32 0.12 91.49
α2 1.0 1.01 0.01 0.30 0.29 0.09 96.81
α3 0.1 0.09 0.01 0.30 0.29 0.09 93.62
Survival model of no-progression population
β00 −1.0 −0.98 0.02 0.22 0.22 0.05 93.62
β01 1.0 0.98 0.02 0.24 0.25 0.06 96.81
β02 0.2 0.22 0.02 0.23 0.24 0.05 91.49
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Table 4.18: Simulation Results when σ2 = 1 and n = 400 with β3 = 1.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.50 0.00 0.28 0.26 0.08 94.68
β11 1.0 1.04 0.04 0.22 0.22 0.05 94.68
β12 0.0 0.01 0.01 0.16 0.16 0.03 91.49
Gap time model of progression population
β20 −0.3 −0.34 0.04 0.27 0.27 0.07 92.55
β21 −0.5 −0.52 0.02 0.24 0.24 0.06 95.74
β22 0.6 0.61 0.01 0.16 0.17 0.03 96.80
β23 −0.5 −0.50 0.00 0.23 0.21 0.05 93.62
β24 0.5 0.50 0.00 0.17 0.20 0.03 98.94
β25 −0.4 −0.38 0.02 0.30 0.31 0.10 97.87
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Table 4.19: Simulation Results when σ2 = 1 and n = 1000 with β3 = 1.
True APE Bias SD ASD MSE CP
σ2 1.0 0.97 0.03 0.15 0.14 0.02 93.02
Susceptibility Model
α0 1.6 1.61 0.01 0.17 0.17 0.03 94.19
α1 −1.8 −1.82 0.02 0.21 0.20 0.04 95.35
α2 1.0 0.99 0.01 0.18 0.18 0.03 95.35
α3 0.1 0.10 0.00 0.18 0.18 0.03 96.51
Survival model of no-progression population
β00 −1.0 −0.99 0.01 0.12 0.14 0.01 98.83
β01 1.0 1.03 0.03 0.15 0.15 0.02 97.67
β02 0.2 0.23 0.03 0.12 0.15 0.02 98.83
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Table 4.20: Simulation Results when σ2 = 1 and n = 1000 with β3 = 1.
Disease progression model of progression population
True APE Bias SD ASD MSE CP
β10 −0.5 −0.53 0.03 0.19 0.17 0.04 91.86
β11 1.0 1.00 0.00 0.14 0.13 0.02 97.67
β12 0.0 −0.00 0.00 0.09 0.10 0.01 98.83
Gap time model of progression population
β20 −0.3 −0.30 0.00 0.19 0.17 0.04 91.86
β21 −0.5 −0.50 0.00 0.14 0.15 0.02 98.83
β22 0.6 0.60 0.00 0.10 0.10 0.01 98.83
β23 −0.5 −0.51 0.01 0.14 0.13 0.02 96.51
β24 0.5 0.52 0.02 0.13 0.13 0.02 96.51
β25 −0.4 −0.43 0.03 0.20 0.19 0.04 94.19
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Table 4.21: Simulation Results when σ2 = 2.25 and n = 400 with β3 = 1.
true APE bias SD ASD MSE CP
σ2 2.25 2.22 0.03 0.34 0.38 0.12 97.80
Susceptibility Model
α0 1.6 1.65 0.05 0.29 0.27 0.09 93.41
α1 −1.8 −1.84 0.04 0.35 0.33 0.12 92.31
α2 1 0.98 0.02 0.28 0.28 0.08 95.60
α3 0.1 0.09 0.01 0.30 0.30 0.09 96.70
Survival model of no-progression population
β00 −1 −1.01 0.01 0.26 0.23 0.07 89.01
β01 1 0.96 0.04 0.25 0.25 0.06 97.80
β02 0.2 0.21 0.01 0.28 0.24 0.08 93.40
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Table 4.22: Simulation Results when σ2 = 2.25 and n = 400 with β3 = 1.
Disease progression model of progression population
true APE bias SD ASD MSE CP
β10 −0.5 −0.46 0.04 0.31 0.33 0.10 94.51
β11 1 1.03 0.03 0.30 0.26 0.07 94.51
β12 0 0.01 0.01 0.20 0.20 0.04 93.41
Gap time model of progression population
β20 −0.3 −0.30 0.00 0.33 0.34 0.11 94.51
β21 −0.5 −0.49 0.01 0.28 0.27 0.08 95.61
β22 0.6 0.61 0.01 0.19 0.18 0.04 89.01
β23 −0.5 −0.47 0.03 0.28 0.26 0.07 93.41
β24 0.5 0.53 0.03 0.26 0.24 0.07 93.41
β25 −0.4 −0.43 0.03 0.37 0.34 0.14 92.31
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Table 4.23: Simulation Results when σ2 = 2.25 and n = 1000 with β3 = 1.
true APE bias SD ASD MSE CP
σ2 2.25 2.12 0.13 0.34 0.36 0.13 96.59
Susceptibility Model
α0 1.6 1.63 0.03 0.29 0.27 0.09 94.32
α1 −1.8 −1.86 0.06 0.38 0.32 0.15 89.77
α2 1 0.99 0.01 0.28 0.28 0.08 95.45
α3 0.1 0.08 0.02 0.30 0.30 0.09 95.45
Survival model of no-progression population
β00 −1 −1.03 0.03 0.27 0.23 0.07 87.50
β01 1 0.96 0.04 0.27 0.25 0.07 94.32
β02 0.2 0.20 0.00 0.30 0.24 0.09 93.18
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Table 4.24: Simulation Results when σ2 = 2.25 and n = 1000 with β3 = 1.
Disease progression model of progression population
true APE bias SD ASD MSE CP
β10 −0.5 −0.44 0.06 0.32 0.32 0.11 94.32
β11 1 1.00 0.00 0.29 0.26 0.08 95.45
β12 0 0.01 0.01 0.21 0.20 0.04 93.18
Gap time model of progression population
β20 −0.3 −0.28 0.02 0.34 0.33 0.12 93.18
β21 −0.5 −0.47 0.03 0.28 0.26 0.08 97.73
β22 0.6 0.59 0.01 0.19 0.18 0.04 90.91
β23 −0.5 −0.49 0.01 0.25 0.26 0.07 96.59
β24 0.5 0.53 0.03 0.26 0.24 0.07 92.05
β25 −0.4 −0.41 0.01 0.36 0.33 0.13 94.32
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Chapter 5
Time-Varying Coefficient Cox
Model for Access Change in
Dialysis Study
5.1 Introduction
Dialysis treatment is necessary to sustain life for patients with end stage renal
disease (ESRD). Dialysis treatment requires access to the bloodstream to deliver
a high enough blood flow. Catheter (CATH) and arteriovenous (AV) are common
methods of vascular access. The influence of using CATH and AV on the mortality
risk is of great interest. Studies show that patients using CATH have a greater
mortality risk than those using AV access (Astor, Eustace, Powe, Klag, Fink and
Coresh 2005, Allon, Daugirdas, Depner, Greene, Ornt and Schwab 2006, Wys-
trychowski, Kitzler, Thijssen, Usvyat, Kotanko and Levin 2009, Lacson, Wang,
Lazarus and Hakim 2009, Bradbury, Chen, Fumiss, Pisoni, Keen, Mapes and
Krishnan 2009, Ng, Hung, Wu and Ko 2014). In practice, CATH, as a method of
67
vascular access in unprepared HD situations, usually serves patients only in the
short term and patients may switch to AV as the method of long term vascular
access. To evaluate the impact of time at access change on mortality risk may
play an essential role to maximize the benefit from vascular access. However, pre-
vious studies have left this question unanswered. This chapter aims to investigate
the association between time of access change and mortality risk through the Cox
proportional hazard (Cox PH) model with time-varying coefficient, as well as to
provide evidence for the hypothesis that patients with early access change from
CATH to AV have lower mortality risk than those with late access change.
5.2 The Data
The data set consists of patients who were treated with HD at Fresenius medi-
cal care. The study lasted from January 2010 to December 2014. The demographic
characteristics, age, race, male, hispanic and height, are recorded for all patients.
Note race denotes white as 1 and all others as 0. The following 12 measures
of baseline characteristics are taken: diabetic, pre-dialysis systolic blood pres-
sure (presbp), pre-dialysis diastolic blood pressure (predbp), pre-dialysis weight
(preweight), post-dialysis weight (postweight), the blood flow rate (QB), the dial-
ysis fluid flow rate (QD), interdialytic weight gain (idwg), ultrafiltration rate (ufr),
albumin (album), EPO use (epo), and neutrophil-to-lymphocyte ratio (nlr). Vas-
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cular accesses are defined as catheter (CATH) and arteriovenous (AV), where AV
includes patients with fistulas or grafts.
3835 patients who began HD with vascular access as CATH are included. A
categorical variable switch is defined to be 1 when the access change is observed
and 0 when no access change is observed during the study. The continuous vari-
able switchtime denotes time at access change since the initiation of dialysis. The
access change and censor rates are 57.57% and 74.97%, respectively. The baseline
characteristic measures are taken as the measures in the first month.
For demographic characteristics, the average age is 65.97 with SD 15.34, the
average height is 167.66 cm with SD 12.45, more patients are white (67.77% with
SD 46.74), a slightly greater number of male patients than female ones (54.60%
with SD 49.79), less than one sixth of patients are hispanic (13.06%, with SD
33.70) and more diabetic patients are enrolled (60.34%, 48.93). The descriptive
statistics for baseline characteristics is summarized in Table 5.1 with two columns,
mean and standard deviation (SD). We note that the variation of epo is very large
in (SD: 5392.16). The primary outcome is the observed survival time with the
unit as year (eventtime).
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The overall goal of this study is to investigate the time-varying effect of access
change. We apply the Cox PH model with time-varying coefficient to explore the
relation between survival hazard and time at access change.
5.3 Time-Varying Coefficient Cox Model
Various methods have been proposed to fit a Cox PH model with varying co-
effcient. While the association between the switch and failure event also varies
with the time of switch, a Cox PH model with time-varying coefficient allows us to
quantify this relation between switch and failure time through assuming that the
coefficient of the time-dependent indicator of the switch event is a nonparametric
function of time at switch.
Define TD as the failure time, TV as the time of access change and U(t) as
the access change event as time-dependent covariate, that is U(t) equals to 1 as
t ≥ TV and 0 as t < TV for TD = t. We consider the following Cox PH with
varying coefficient
hD(t|U(t),X) = h0(t)exp [β(s)U(t) + γX] , (5.1)
where h0(t) denotes baseline hazard and hD(t) denotes hazard function for failure.
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Table 5.1: Means and standard deviations of variables
mean SD
diabetic(%) 60.34 48.93
preweight (kg) 83.81 23.54
postweight (kg) 81.97 23.22
presbp (mmHg) 143.68 21.74
predbp (mmHg) 76.47 13.21
QB (mL/min) 367.63 42.90
QD (mL/min) 661.88 91.95
idwg (%) 2.93 1.35
ufr (%) 6.76 3.24
album (g/dl) 3.65 0.37
epo (units) 5040.97 5392.16
nlr (unitless) 6.01 5.53
eventtime 1.25 1.27
switchtime 0.19 0.34
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5.4 Estimation
Perperoglou, le Cessie and van Houwelingen (2006) proposed a fast routine for
fitting the Cox PH model with time-varying effects of the covariates, and Thomas
and Reyes (2014) described the survival estimation in SAS and R for such a
model. Nan, Lin, Lisabeth and Harlow (2005) proposed a Cox PH model with
time-varying coefficient to investigate the association between age at a marker
event, defined as a specific bleeding pattern change, and age at menopause, where
both events are subject to censoring and their association varies with age at the
marker event.
In this section, we will introduce the method to estimate the nonparametric
function β(s) using the regression spline method. Specifically, we approximate
β(s) using the natural cubic B-spline basis. Let K be the number of interior
knots. The locations of knots are usually chosen such that an equal number of
observed data values sits between any two adjacent knots, or knots are placed
equally spaced through the study time.
The function β(s) can be parameterized using K + 2 natural cubic B-spline
basis functions Bj(s) for j = 1, . . . , K + 2 as
β(s) =
K+2∑
j=1
θjBj(s). (5.2)
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Substituting β(s) by the approximation of B-spline in equation (5.2), we could
rewrite model (5.1) as
hDu(t|U(t),X) = h0(t)exp
[
θTU˜(t) + γX
]
(5.3)
where θ = (θ1, . . . , θK+2)
T and U˜(t) = {B1(s)Z(t), . . . , BK+2(s)Z(t)}T .
Now model (5.3) becomes a standard Cox proportional hazards model with
time-dependent covariate vector U˜(t) and the baseline covariate vector X. There-
fore, we can obtain the estimates of parameter (θ, γ) through partial likelihood
estimators method. The no-parametric function β(s) can be estimated by equa-
tion (5.2).
Standard methods may be applied to get estimates of β(s) and γ when the
knots are fixed. In the following we adopt the GCV method in Nan et al. (2005)
to select the number of knots based on data.
Nan et al. (2005) considered the case when the cumulative baseline hazard
function H0(t) is unknown and is estimated by the Breslow estimator,
Hˆ0(t) =
∫ t
0
[ n∑
i=1
I(Yi ≥ u)exp
[
βˆ(Si)Zi(u) + γˆ
′Xi
] ]−1[ n∑
i=1
dNi(u)
]
, (5.4)
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where Ni(u) denotes the failure event counting process, I(Yi ≥ u) denotes at
risk process.
A series of Cox PH models as in (5.3) are fitted for a range of the number of
interior knots K. For each choice of K, the cumulative baseline hazard function
estimator Hˆ0(t,K) is calculated. For a given number of knots K, the likelihood
function of (θ, γ) is obtainable and can be maximized using an iterated reweighed
least square algorithm. Denote the estimators of (θ, γ) at the lth iteration are
(θˆ(l), γˆ(l)), the working weight wi and the working dependent variable yi for subject
i are written as
wi =
1
2
Hˆ0(Yi)exp
[
θˆ′(l)U˜i(Yi) + γˆ
′
(l)Xi
]
,
yi = θˆ
′
(l)Z˜i(Yi) + γˆ
′
(l)Xi +4i/(2wi)− 1. (5.5)
where 4i denotes the censoring indicator. We calculates (θˆ(l+1), γˆ(l+1)) by mini-
mizing
∑n
i=1 ωi
[
yi − θ′U˜i(Yi)− γ′Xi
]2
. Denote the working dependent variable,
the working weight matrix, and the predicted value vector at convergence by
yˆ = (yˆ1, . . . , yˆn)
′,Wˆ = diag(wˆ1, . . . , wˆn), and fˆ = (fˆ1, . . . , fˆn)′. Note that fˆ can
be calculated as fˆ = Xˆ(Xˆ′WˆXˆ)−1XˆWˆyˆ = Hˆyˆ, where Hˆ is the linearized hat
matrix. The GCV criterion as a function of knots K, is given by
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GCV(K) =
∑n
i=1wi(yˆi − fˆi)2
(1− hˆ)2 , (5.6)
where hˆ is the average of the diagonal elements of Hˆ. We substitute different
baseline hazard estimators for different K into (5.5) and (5.6). We then select K to
minimize GCV(K), call it K∗, and obtain corresponding baseline hazard estimator
Hˆ0(t,K∗). Recalculating the GCV statistics in (5.6) using (5.5) by substituting
the Hˆ0(t,K∗) for each possible value of K and select a new K, as updated K∗,
that minimize GCV (K). Note a common Hˆ0(t;K) is used to calculate GCV for
different possible values of K. Above procedure is repeated until the chosen K∗
at the current step is the same as the K∗ at the previous step.
5.5 Analysis of the Dialysis Study
The Cox PH model with time-varying coefficient, including the time-dependent
indicator of access change, switch, and all demographic and baseline characteris-
tics, is fitted with the introduced main dataset of dialysis study to explore the
time-varying effect of access change on mortality over time. Observed times at
access change are used to generate the natural cubic B-spline basis function for
estimating β(s). Using a GCV algorithm, the obtained optimal number of interior
knots is 5. The obtained estimates and the plot of the estimate of β(s) for this
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model are summarized in Table 5.2, and Figure 5.1.
Figure 5.1 describes the effect of access change on hazard throughout the study
time. The X-axis stands for the time line for access change, while Y-axis stands
for the hazard ratio of access change. The short blue segments at the bottom
indicate the participating subjects. The red dashed line denotes reference, which
takes value 1, as no impact on mortality risk. The solid black line is the estimated
effect of access change using the B-spline basis, and the dashed navy lines are
the 95% CI for the effect of access change. We observe that the 95% CI is well
below the red reference line before 0.5 year. This indicates that the effect of access
change before 0.5 year is significantly different from zero. Specifically, the access
change at early stage has significant negative effect on mortality risk. The 95%
CI for effect of access change after 0.5 year, however, contains one, implying that
the impact on mortality risk is not significant. That is, the late access change has
small impact on mortality risk.
The effects from eight demographic and baseline characteristics are found to
be significant. The positive effects from two demographic and three baseline char-
acteristics, age, race, diabetic, idwg, and ufr, on mortality risk appear to be signifi-
cant. The negative effects from one demographic and two baseline characteristics,
hispanic, presbp and album, on mortality risk appear to be significant.
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Table 5.2: Estimates for Cox PH model with time-varying coefficient
Cox PH model w/ time-varying coef.
EST exp(EST) p-value
age 0.04 (0.00) 1.04 <0.001
race 0.42 (0.08) 1.53 <0.001
male -0.02 (0.08) 0.98 0.85
hispanic -0.34 (0.11) 0.71 0.00
height (cm) -0.00 (0.00) 0.92. 0.60
diabetic 0.24 (0.07) 1.27 0.00
preweight (kg) -0.08 (0.04) 0.92 0.08
postweight (kg) 0.08 (0.05) 1.08 0.08
presbp (mmHg) -0.01 (0.00) 0.99 <0.001
predbp (mmHg) - 0.00 (0.00) 1.00 0.81
QB (mL/min) -0.00 (0.00) 1.00 0.24
QD (mL/min) -0.00 (0.00) 1.00 0.41
idwg (%) 0.09 (0.04) 1.10 0.01
ufr (%) 0.04 (0.02) 1.04 0.01
album (g/dl) -0.54 (0.10) 0.58 <0.001
epo (units) 0.00 (0.00) 1.00 0.20
nlr (unitless) 0.01 (0.01) 1.01 0.18
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Figure 5.1: Hazard ratio of the effect of access change (eβ(s)): solid black line is
the estimated effect of access change, and dashed navy lines are 95% CI for the
effect of access change over the first year of the study.
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Chapter 6
Accelerated Failure Time Model
for Access Change in Dialysis
Study
6.1 Introduction
An accelerated failure time (AFT) model as an extension of Robins and Tsiatis
(1991)’s model is considered. For a patient who has access change, the latent event
time is defined as an abstract quantity represents the patient’s survival time that
would have been if this patent had no access change. For a patient with access
change, the latent event time is the same as his/her survival time. The effect of
access change then can be estimated through the likelihood function. Given time
at access change, Robins and Tsiatis (1991) estimated the effect of access change
from a conditional likelihood function. While we model time at access change as
a random variable, we estimate the effect of access change from a full likelihood
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function.
6.2 Accelerated Failure Time Model with Latent
Survival Time
We are using the following notations in this chapter,
(1) Indicator for access at the initiation of dialysis R =

0 CATH,
1 AV.
(2) Indicator for censoring to failure time δ =

0 failure time censored,
1 failure time uncensored.
(3) Indicator for access change V =

0 no access change,
1 access change.
(4) T0 denotes observed failure time for CATH, as the reference failure time.
(5) S0(t) denotes the survival function for failure time for patients with CATH.
(6) f0(t) denotes the probability density function for failure time for patients
with CATH.
(7) T1 denotes observed time at access change when initial access as CATH.
(8) S1(t) denotes the survival function for time at access change when initial
access as CATH.
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(9) f1(t) denotes the probability density function for time at access change when
initial access as CATH.
(10) TV denotes time at access change.
(11) SV (t) denotes the survival function for time at access change.
(12) fV (t) denotes the probability density function for time at access change.
(13) TD denotes failure time.
(14) SD(t) denotes the survival function for failure time.
(15) fD(t) denotes the probability density function for failure time.
(16) TL denote failure time when the access change is present.
(14) SL(t) denotes the survival function for failure time when the access change
is present.
(15) fL(t) denotes the probability density function for failure time when the
access change is present.
(16) exp [α1] denotes the effect from AV on failure time when no access change
occurs.
(17) exp [α2] denotes the effect from AV on time at access change.
(18) exp [α3] denotes effect of access change from CATH to AV.
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(19) exp [α4] denotes effect of access change from AV to CATH.
(20) X represents baseline covariates.
(21) Z represents covariates collected at access change as prognostic factors for
the decision to access change.
(22) exp [β1] denotes the effect from baseline covariates on failure time when no
access change occurs.
(23) exp [β2] denotes the effect from baseline covariates on time of access change
before access change occurs.
(24) exp [β3] denotes the effect from baseline covariates on time at access change
to death.
(25) exp [β4] denotes effect from prognostic factors on time at access change to
death.
The observed event times and times at access change are assumed to be
TD
d
= exp [α1R + β1X]T0, (6.1)
TV
d
= exp [α2R + β2X]T1. (6.2)
Consider the situation where patients are allowed to have access change, using
Robins and Tsiatis (1991)’s model, for a patient with access change at time TV ,
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the latent event time TD is defined as an abstract quantity represents the patient’s
survival time that would have been if this patent had no access change while the
actual event time TL is defined as the survival time when the access change is
present. For a patient without access change, the latent event time is the same as
his/her survival time. A simplified graph describes the relation of TL and TD in
Figure 6.1.
For patients with access change from CATH to AV or AV to CATH, as TD ≥
TV , the latent and observed event times can be related as follows
TL
d
= TV + exp [α3(1−R) + α4R + β3X + β4Z] (TD − TV ). (6.3)
6.3 Estimation
In this section, we construct the full likelihood by the following steps: (1)
categorize subjects into four group according to their experienced events, (2) de-
rive the likelihood function contributed by each group and (3) construct the full
likelihood function with the contributed part by each group.
Let Y denote the observed failure time, and S denote the observed time at
access change. V = 0 indicates the failure occurs before access change, while
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V = 1 indicates the failure occurs after access change. δ = 1 denotes uncensored
and δ = 0 denotes censored. The observed data can be divided into four groups
of observations:
Group 1. Subjects are observed to fail at time Y without access change event
occurring. These subjects have V = 0, TD = Y and δ = 1.The contribution to the
likelihood function is
fD(Y |R,X)SV (Y |R,X) = exp [−α1R− β1X] f0
(
exp [−α1R− β1X]Y
)
S1
(
exp [−α2R− β2X]Y
)
. (6.4)
Group 2. The subjects are observed with time at access change S and fail at
time Y . The subjects have V = 1, δ = 1, TL = Y , TV = S. The contribution to
the likelihood function is
fL,V (Y, S|R,X,Z)
= fV (S|R,X)fL(Y |TV = S,R,X,Z)
= exp [−α2R− β2X] f1
(
exp [−α2R− β2X]S
)
× exp [−α1R− β1X− α3(1−R)− α4R− β3X− β4Z]
× f0
(
exp [−α1R− β1X]
(
S + exp [−α3(1−R)− α4R− β3X− β4Z] (Y − S)
))
.
(6.5)
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Group 3. The subjects are observed with time at access change S and cen-
sored at time Y . These subjects have V = 1, δ = 0, TL ≥ Y , and TV = S. The
contribution to the likelihood function is
P (TL ≥ Y, TV = S|R,X,Z)
= fV (S|R,X)P (TL ≥ Y |TV = S,R,X,Z)
= fV (S|R,X)SD(S + exp [−α3(1−R)− α4R− β3X− β4Z] (Y − S)|R,X,Z)
= exp [−α2R− β2X] f1
(
exp [−α2R− β2X]S
)
× S0
(
exp [−α1R− β1X]
(
S + exp [−α3(1−R)− α4R− β3X− β4Z] (Y − S)
))
.
(6.6)
Group 4. Subjects are only observed to be censored at time Y without access
change and death. These subjects have V = 0, δ = 0 and TD > Y ; or, they may
have V = 1, δ = 0 and TV > Y . These subjects may also have V = 1, δ = 0 and
TL > TV > Y , The contribution to the likelihood function is
P (TD ≥ Y |R,X)P (TV ≥ Y |R,X)
= SD(Y |R,X)SV (Y |R,X)
= S0
(
exp [−α1R− β1X]Y
)
S1
(
exp [−α2R− β2X]Y
)
. (6.7)
Based on above four categorizations of group, the full log likelihood is derived
as below:
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logL(·|Y,S) = δ(1− V )(log fD(Y |R,X) + logSV (Y |R,X))
+ δV (log fV (S|R,X) + log fL(Y |TV = S,R,X,Z)
+ (1− δ)V (log fV (S|R,X) + logP (TL ≥ Y |TV = S,R,X,Z))
+ (1− δ)P (V = 1)(logSD(Y |R,X) + logSV (Y |R,X))
+ (1− δ)P (V = 0)(logSD(Y |R,X) + logSV (Y |R,X)). (6.8)
6.4 Simulation Study
We set S0(t) = exp [−t], S1(t) = exp [−t]. Suppose α1 = 1, α2 = 1.5, β1 = 1,
β2 = 1.5, β3 = 0.2, β4 = 0.3, α3 = 5, and α4 = −1. The initial access R is as-
signed to be 0 for the first half of the subjects and 1 for the other half. The failure
time TD and the time at access change TV are generated using equation (6.2) and
(6.3). We assign the indicator for access change V to be 0 when TD < TV , and
to be 1 when TD > TV . For patients with V = 1, using equation 6.3, we further
generated TL with obtained TD and TV . The baseline covariate X
i.i.d.∼ Ber(0.7)
and the prognostic covariate Z ∼ Uni(0, 1) Assume censoring time assumes to be
C ∼ Uniform[0, 72]. The censoring indicator δ takes 1 when TL ≤ C and 0 when
TL > C. Denote Y = min(TL, C) as the observed failure time and observed time
at access change S = TV for V = 1. The average access change and censoring rate
for 100 sets of data with sample size as 500 and 1000 are (35.79%, 29.18%) and
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(35.91%, 29.35%), respectively.
From 100 simulated datasets, the obtained MSE for the majority average of
estimates are below 0.5 except for the estimate for α3 of sample size 500. The
slightly elevated MSE of α3 is attributed to the increase SD between the estimates
from 100 simulated dataset. All CP are close to 95% for both sample size 500 and
1000. We conclude that the estimation method performed well.
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Table 6.1: Simulation result with access change rate as 35.79% and censoring rate
as 29.18% and n = 500.
n = 500
True APE Bias ASD SD MSE CP
α1 1 0.99 0.01 0.10 0.11 0.01 93%
α2 1.5 1.48 0.02 0.13 0.15 0.02 93%
α3 5 5.32 0.32 7.27 1.91 3.75 98%
α4 −1 −1.03 0.03 0.34 0.36 0.13 95%
β1 1 1.02 0.02 0.09 0.09 0.01 94%
β2 1.5 1.47 0.03 0.11 0.11 0.01 94%
β3 2.5 2.53 0.03 0.34 0.37 0.14 97%
β4 1.5 1.48 0.02 0.53 0.49 0.24 97%
6.5 Description of Dataset
Among total of 14468 patients, 6621 patient began HD with vascular access
as CATH, with 3437 of them switched to AV, and 7245 patients began HD with
vascular access as AV, with 1195 of them switched to CATH. A categorical vari-
able switch is defined to be 1 when the access change is observed and 0 when no
access change is observed during the study. The continuous variable switchtime
denotes time at access change. The average access change and censor rates are
33.03% and 74.18%, respectively. The access change rate is 51.91% for patient
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Table 6.2: Simulation result with access change rate as 35.91% and censoring rate
as 29.35% and n = 1000.
n = 1000
True APE Bias ASD SD MSE CP
α1 1 1.00 0.00 0.07 0.08 0.01 89%
α2 1.5 1.47 0.03 0.09 0.08 0.01 95%
α3 5 5.19 0.19 0.40 0.43 0.22 97%
α4 −1 −1.01 0.01 0.24 0.23 0.05 95%
β1 1 1.02 0.02 0.06 0.07 0.001 93%
β2 1.5 1.48 0.02 0.08 0.07 0.01 99%
β3 2.5 2.49 0.01 0.24 0.25 0.06 93%
β4 1.5 1.46 0.04 0.38 0.41 0.17 93%
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with initial access as CATH and is 16.49% for patients with initial access as AV.
The baseline characteristic measures are taken as the measures in the first month.
The descriptive statistics for demographic, baseline and prognostic character-
istics are summarized in Table 6.3 and 6.4. The statistics are presented in the
format of mean (SD). The primary outcome is the observed survival time with
year as unit (eventtime). While more patients of race:white than all other race
(63.60%) are enrolled, there are a lightly greater number of male than female
patients (56.41%). Less than one sixth of patients are hispanic (14.07%). More
diabetic patients are enrolled (60.62%). Note that the variation of epo is very
large in both datasets (SD: 5419.62).
The overall goal of this study is to investigate the effect of access change from
CATH to AV and from AV to CATH on survival time, assuming time at access
change, TV , as a random variable.
6.6 Analysis with AFT model for Dialysis Dataset
The AFT model is fitted with the dialysis dataset to explore the effect of access
change from CATH to AV and from AV to CATH. Estimates are summarized in
Table 6.5 - 6.10.
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Table 6.3: Descriptive statistics of demographic characteristics
mean SD
age 66.09 15.01
race(%) 63.60 48.12
male(%) 56.41 49.59
hispanic(%) 14.07 34.77
height (cm) 167.72 12.47
The positive effects of AV on survival and time at access change are found
to be significant. While the positive effect of access change from CATH to AV
appear to be significant, the effect of access change from AV to CATH is found to
be insignificant. Specifically, the effect of AV on survival time for patients without
access change is to prolong the time by the factor 2.14 with 95% confidence inter-
val (1.95, 2.32), while the effect of AV on time at access change is to prolong the
time by the factor 11.70 with 95% confidence interval (10.91, 12.55). The effect of
access change from CATH to AV on survival time is to prolong the time by the
factor 5.58 with 95% confidence interval (1.08, 28.79). Note that effects of stay-
ing with CATH on survival time and time at access change are defined as reference.
In Tables 6.7 and 6.8, two negative and one positive demographic effects, age,
race and hispanic, on survival are found to be significant for patients without
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Table 6.4: Descriptive statistics of baseline and prognostic characteristics
baseline prognostic
mean SD mean SD
diabetic(%) 60.62 48.86
preweight (kg) 83.68 23.39 83.41 24.10
postweight (kg) 81.60 23.01 81.20 22.99
presbp (mmHg) 146.06 21.73 147.26 21.22
predbp (mmHg) 76.40 12.93 77.56 12.95
QB (mL/min) 380.14 57.74
QD (mL/min) 667.79 93.37
idwg (%) 2.66 1.39
ufr (%) 7.63 3.57 7.73 3.19
album (g/dl) 3.59 0.53 3.66 0.46
epo (units) 4972.08 5419.62
nlr (unitless) 5.40 5.02 4.53 4.04
eventtime 1.55 1.39
switchtime 0.18 0.47
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Table 6.5: Estimates for effect from AV for the dialysis dataset
TD TV
EST p-value EST p-value
AV 0.76 (0.04) <0.001 2.46 (0.04) <0.001
access change. Minor positive effect of unit increase in age and negative effect of
being white and an unit increase in height on time at access change are also found
to be significant.
The effects on survival time for patients without access change and the effects
on time at access change from baseline characteristics are summarized in Table
6.9. Six negative effects, diabetic, postweight, idwg, ufr, epo, and nlr, along with
three positive effects, preweight, presbp and album on survival time for patients
without access change are found to be significant. Three negative effects, diabetic,
QD, and nlr, along with three positive effects, QB, idwg and album on time at
access change are found to be significant.
The effects for baseline and prognostic characteristics on survival for patients
with access change are summarized in Table 6.10. Two negative effects, presbp and
album, along with one positive effects, nlr of baseline characteristics on survival
for patients with access change are found to be significant.
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Table 6.6: Estimates for effect of access change for the dialysis dataset
TL
EST p-value
CATH to AV 1.72 (0.84) 0.04
AV to CATH 0.86 (0.85) 0.31
Table 6.7: Estimates for demographic characteristics of the failure time without
access change, TD, and time at access change, TV
TD TV
EST p-value EST p-value
age -0.03 (≈ 0.00) <0.001 ≈ 0.00 (≈ 0.00) <0.001
race -0.33 (0.04) <0.001 -0.08 (0.03) 0.02
male -0.08 (0.04) 0.07 -0.06 (0.03) 0.06
hispanic 0.29 (0.06) <0.001 0.02 (0.04) 0.60
height (cm) 0.00 (≈ 0.00) 0.08 -0.00 (≈ 0.00) <0.001
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Table 6.8: Estimates for demographic characteristics of the failure time with access
change, TL
TL
EST p-value
age -0.00 (≈ 0.00) 0.17
race -0.03 (0.09) 0.75
male -0.01 (0.09) 0.90
hispanic 0.01 (0.12) 0.91
height (cm) -0.00 (≈ (0.00) 0.29
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Patients on CATH without progression and access 
change 
|-------------------------X    TD 
Patients on CATH with progression and access change 
|------------Δ-----------------------X  TL 
Patients on CATH with progression but no access 
change 
|------------Δ---------------X    TD 
 
Patients on AV without progression and access change 
|----------------------------------X    TD 
Patients on AV with progression and access change 
|----------Δ-----------X     TL 
Patients on AV with progression but no access change 
|----------Δ--------------------X   TD 
X: event of failure 
Δ: event of progression and access change 
Δ: event of progression 
--- time on CATH 
--- time on AV 
--- unobserved time (if there were no access change) 
without access change 
TD: observed failure time 
with access change 
TL: observed failure time  
TD: unobserved latent failure time (as if there were 
progression but no access change)  
Figure 6.1: Relation in graph between TD and TL with/without access change.
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Table 6.9: Estimates for baseline characteristics of failure time without access
change (TD) and time at access change (TV )
TD TV
EST p-value EST p-value
diabetic -0.15 (0.04) <0.001 -0.15 (0.03) <0.001
preweight (kg) 0.06 (0.03) 0.01 -0.00 (0.02) 0.88
postweight (kg) -0.06 (0.03) 0.02 0.00 (0.02) 0.91
presbp (mmHg) 0.01 (≈ 0.00) <0.001 -0.00 (≈ 0.00) 0.30
predbp (mmHg) 0.00 (≈ 0.00) 0.61 -0.00 (≈ 0.00) 0.86
QB (mL/min) -0.00 (≈ 0.00) 0.15 0.00 (≈ 0.00) 0.01
QD (mL/min) -0.00 (≈ 0.00) 0.77 -0.00 (≈ 0.00) 0.01
idwg (%) -0.05 (0.02) 0.04 0.07 (0.02) <0.001
ufr (%) -0.05 (0.01) <0.001 0.01 (0.01) 0.12
album (g/dl) 0.68 (0.04) <0.001 0.15 (0.03) <0.001
epo (units) -0.00 (≈0.00) <0.001 0.00 (≈ 0.00) 0.25
nlr (unitless) -0.23 (≈ 0.00) <0.001 -0.01 (≈ 0.00) 0.01
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Table 6.10: Estimates for baseline and prognostic characteristics of failure time
when access change is present (TL)
TL
baseline prognostic
EST p-value EST p-value
diabetic -0.08 (0.09) 0.35
preweight (kg) -0.07 (0.05) 0.10 -0.05 (0.05) 0.24
postweight (kg) 0.06 (0.05) 0.20 0.01 (0.05) 0.15
presbp (mmHg) -0.01 (≈ 0.00) <0.001 0.02 (≈ 0.00) <0.001
predbp (mmHg) 0.01 (0.01) 0.16 -0.02 (0.01) <0.001
QB (mL/min) 0.00 (≈ 0.00) 0.42
QD (mL/min) -0.00 (≈ 0.00) 0.84
idwg (%) 0.06 (0.05) 0.25
ufr (%) 0.03 (0.02) 0.08 -0.01 (0.02) 0.82
album (g/dl) -0.75 (0.09) <0.001 0.91 (0.08) <0.001
epo (units) 0.00 (≈ 0.00) 0.68
nlr (unitless) 0.03 (0.01) <0.001 -0.03 (0.01) <0.001
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Appendix A
SAS code
A.1 SAS code of fitting AFT model
libname out ’/home/grad/chu/’;
data out.simdata1n;
infile "simdata1_expnorm_wonew.txt"; *you could change this
to your own directory where the data is stored;
input id$ R X1 X2 Z V W Y Group;
* R randomization regime;
* Group as 4 categories, indicating switching and censoring status;
* subject id
* V as switching status;
* X1 and X2 are baseline covariates;
* Z covariate collected at disease progression;
* Y observed failure time;
* W progression time;
run;
proc print data=out.simdata1n;
run;
***NLMIXED procedure: The integration method is specified to
take default method, adaptive Gauss-Hermite quadrature
(\textbf{GAUSS}).
The optimization is set to be default algorithm,
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Quasi-Newton Optimization (\textbf{QUANEW}).
The update formula is specified to be the dual Davidon, Fletcher,
and Powell (DFP) update of the Cholesky factor of
the Hessian matrix (\textbf{DDFP}).
The maximum number of quadrature points (\textbf{QMAX})
before the adaptive search is aborted sets to be 100;
proc nlmixed data=out.simdata1n qmax=100 itdetails upd=ddfp;
***specify the parameters with bounds;
**** set initial values;
parms alpha0=1.6 alpha1=-1.8 alpha2=1 alpha3=0.1
beta00=-1 beta01=1 beta02=0.2
beta10=-0.5 beta11=1 beta12=0
beta20=-0.3 beta21=-0.5 beta22=0.6 beta23=-0.5
beta24=0.5 beta25=-0.4;
**assume the linear combination part of each accelerated factor;
lin_e0 = beta00*R + beta01*X1 + beta02*X2;
lin_e1 = beta10*R + beta11*X1 + beta12*X2;
lin_e2 = beta20*R + beta21 *V* (1-R)+ beta22*W+ beta23*X1
+ beta24*X2+beta25*Z;
***the survival functions of $T_D$, $T_U$ and $T_G$ are written
based on equations in chapter 3.;
Correspondent hazard functions are obtained by
the general formula of survival function;
***accelerated factor for T_D (time to death for non progression group),
T_U(time to progression) and T_G(time from progression to death);
e_d = exp(lin_e0);
e_u = exp(lin_e1);
e_g = exp(lin_e2);
***logit model for probability of progression,
pu_1 as probability of progression and
pu_0 as probability of non-progression;
pu_1 = 1/(1+exp(-(alpha0+alpha1*R+alpha2*X1+alpha3*X2)));
pu_0 = 1 - 1/(1+exp(-(alpha0+alpha1*R+alpha2*X1+alpha3*X2)));
***survival function using formula;
*survival function of T_D;
S_d = exp(-Y * e_d);
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*survival function of T_U, for the patients belong to group 2 and 3;
S_u23 = exp(-W * e_u);
*survival function of T_U, for the patients belong to group 4;
S_u4 = exp(-Y * e_u);
*survival function of T_G;
S_g = exp(-(Y-W) *e_g);
***correspondent hazard function;
h_d = e_d;
h_u = e_u;
h_g = e_g;
***specify the contribution to the log likelihood function of subject
who is categorized to belong to Group 1, 2, 3 and 4, respectively
***loglikelihood from 4 group of subjects;
* loglik for group 1(U=0, delta=1);
if (Group=1) then loglik = log (h_d) + log(S_d) + log( pu_0);
* loglik for group 2(U=1, delta=1);
if (Group=2) then loglik = log (h_u) + log(h_g) + log( S_u23)
+ log(S_g) + log( pu_1);
* loglik for group 3(U=1, delta=0);
if (Group=3) then loglik = log (h_u) + log( S_u23)
+ log( S_g) + log(pu_1);
* loglik for group 4(U=1/U=0, delta=1);
if (Group=4) then loglik = log (S_d *pu_0 + S_u4 * pu_1);
*** the full likelihood function;
*** A model statement is then specified
using the option general (loglik)
to describe the distribution of the response variable.
No random statement is specified for this case;
model Y ~ general(loglik);
ods output ParameterEstimates=out.est_wo FitStatistics=out.fit;
run;
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A.2 SAS code of fitting AFT model with a frailty
term
libname out ’/home/grad/chu/’;
data out.simdata1n;
infile "simdata1_expnorm_wnew.txt"; * you should change this
to your own directory where the data is stored;
input id$ R X1 X2 Z V W Y Group;
* R randomization regime;
* Group as 4 categories, indicating switching and censoring status;
* subject id;
* V as switching status;
* X1 and X2 are baseline covariates;
* Z covariate collected at disease progression;
* Y observed failure time;
* W progression time;
run;
proc print data=out.simdata1n;
run;
***NLMIXED procedure: The integration method is specified to
take default method, adaptive Gauss-Hermite quadrature
(\textbf{GAUSS}).
The optimization is set to be default algorithm,
Quasi-Newton Optimization (\textbf{QUANEW}).
The update formula is specified to be the dual Davidon, Fletcher,
and Powell (DFP) update of the Cholesky factor of
the Hessian matrix (\textbf{DDFP}).
The maximum number of quadrature points (\textbf{QMAX})
before the adaptive search is aborted sets to be 100;
proc nlmixed data=out.simdata1n qmax=100 itdetails upd=ddfp;
***specify the parameters with bounds;
**** set initial values;
parms sigma2=1 alpha0=1.6 alpha1=-1.8 alpha2=1 alpha3=0.1
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beta00=-1 beta01=1 beta02=0.2
beta10=-0.5 beta11=1 beta12=0
beta20=-0.3 beta21=-0.5 beta22=0.6 beta23=-0.5
beta24=0.5 beta25=-0.4;
**assume the linear combination part of accelerated factor;
lin_e0 = beta00*R + beta01*X1 + beta02*X2;
lin_e1 = beta10*R + beta11*X1 + beta12*X2;
lin_e2 = beta20*R + beta21 *V* (1-R)+ beta22*W
+ beta23*X1+ beta24*X2+beta25*Z;
***the survival functions of $T_D$, $T_U$ and $T_G$ are written
based on equations in chapter 3.
Correspondent hazard functions are obtained
by the general formula of survival function
***accelerated factor for T_D (time to death for non progression group),
T_U(time to progression) and T_G(time from progression to death);
***omega stands for frailty;
e_d = exp(lin_e0);
e_u = exp(lin_e1 + omega);
e_g = exp(lin_e2 + omega);
***logit model for probability of progression,
pu_1 as probability of progression and
pu_0 as probability of non-progression;
pu_1 = 1/(1+exp(-(alpha0+alpha1*R+alpha2*X1+alpha3*X2)));
pu_0 = 1 - 1/(1+exp(-(alpha0+alpha1*R+alpha2*X1+alpha3*X2)));
***survival function using formula;
*survival function of T_D;
S_d = exp(-Y * e_d);
*survival function of T_U, for the patients belong to group 2 and 3;
S_u23 = exp(-W * e_u);
*survival function of T_U, for the patients belong to group 4;
S_u4 = exp(-Y * e_u);
*survival function of T_G;
S_g = exp(-(Y-W) *e_g);
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***correspondent hazard function;
h_d = e_d;
h_u = e_u;
h_g = e_g;
***specify the contribution to the log likelihood function of subject
who is categorized to belong to Group 1, 2, 3 and 4, respectively
***loglikelihood from 4 group of subjects;
* loglik for group 1(U=0, delta=1);
if (Group=1) then loglik = log (h_d) + log(S_d) + log( pu_0);
* loglik for group 2(U=1, delta=1);
if (Group=2) then loglik = log (h_u) + log(h_g) + log( S_u23)
+ log(S_g) + log( pu_1);
* loglik for group 3(U=1, delta=0);
if (Group=3) then loglik = log (h_u) + log( S_u23)
+ log( S_g) + log(pu_1);
* loglik for group 4(U=1/U=0, delta=1);
if (Group=4) then loglik = log (S_d *pu_0 + S_u4 * pu_1);
*** the full likelihood function;
model Y ~ general(loglik);
*** random statement is used to define normal random effects,
as frailty term, with subjects specified
using the keyword \textbf{subject} in this statement.
This will result in a longormal component.
*** specify the distribution of frailty as normal
and the random factor assumed to be the variation among subjects;
random omega ~ normal(0,sigma2) subject=id;
ods output ParameterEstimates=out.est_w FitStatistics=out.fit;
run;
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